The present invention relates to a control system for controlling a medical treatment device. More particularly, the present application relates to a system and method for electrically ablating tissue of a patient.
Devices for delivering therapeutic energy such as an ablation device using irreversible electroporation (IRE) include a pulse generator and one or more electrodes coupled to the generator. The pulse generator delivers the therapeutic energy to a targeted tissue through the electrodes, thereby causing ablation of the tissue.
Once a target treatment area/region is located within a patient, the electrodes of the device are placed in such a way as to create a treatment zone that surrounds the target treatment region.
Prior to treatment, a treatment planning system is used to generate an estimated treatment region that completely covers the target treatment region. The estimated region is used by a physician to plan where to place the electrodes in the patient.
This can be effective when the target area is relatively small, e.g., less than 2 cm in length. However, when the target area is much larger, e.g., larger than 3 cm in length, the physician is forced to use a large number of electrodes, e.g., 4 or more electrodes. This makes accurately placing the electrodes much more difficult as moving one electrode affects the spacing from all other electrodes.
Alternatively, the large target area can be divided into two or more smaller areas and the treatment procedure for one area can be repeated to cover the other divided areas. However, this makes the entire treatment procedure much longer. The longer procedure makes it riskier for the patient since the patient would have to stay on an operating table much longer with an exposed body portion to be treated. The longer procedure also makes the procedure more expensive.
Therefore, it would be desirable to provide a system and method for electrically ablating tissue of a patient more safely and efficiently.
According to one aspect of the invention, a system for electrically ablating tissue of a patient through a plurality of electrodes is provided. The system includes a memory, a processor and a treatment control module stored in the memory and executable by the processor. The treatment control module generates an estimated treatment region by taking into account the relationship between the ablation size and the number of pulses to be applied. This allows treatment of relatively large target ablation regions more efficiently and accurately.
According to another aspect of the invention, a method of electrically ablating tissue of a patient through a plurality of electrodes is provided. The method includes receiving positions of a plurality of electrodes and generating an estimated treatment region based on the received electrode positions and the number of pulses to be applied.
Throughout the present teachings, any and all of the one, two, or more features and/or components disclosed or suggested herein, explicitly or implicitly, may be practiced and/or implemented in any combinations of two, three, or more thereof, whenever and wherever appropriate as understood by one of ordinary skill in the art. The various features and/or components disclosed herein are all illustrative for the underlying concepts, and thus are non-limiting to their actual descriptions. Any means for achieving substantially the same functions are considered as foreseeable alternatives and equivalents, and are thus fully described in writing and fully enabled. The various examples, illustrations, and embodiments described herein are by no means, in any degree or extent, limiting the broadest scopes of the claimed inventions presented herein or in any future applications claiming priority to the instant application.
One embodiment of the present invention is illustrated in
In the embodiment shown, each probe 22 includes either a monopolar electrode or bipolar electrodes having two electrodes separated by an insulating sleeve. In one embodiment, if the probe includes a monopolar electrode, the amount of exposure of the active portion of the electrode can be adjusted by retracting or advancing an insulating sleeve relative to the electrode. See, for example, U.S. Pat. No. 7,344,533, which is incorporated by reference herein. The generator 10 is connected to a treatment control computer 40 having input devices such as keyboard 12 and a pointing device 14, and an output device such as a display device 11 for viewing an image of a target treatment region such as a lesion 300 surrounded by a safety margin 301. The pulse generator 10 is used to treat a lesion 300 inside a patient 15. An imaging device 30 includes a monitor 31 for viewing the lesion 300 inside the patient 15 in real time. Examples of imaging devices 30 include ultrasonic, CT, MRI and fluoroscopic devices as are known in the art.
The present invention includes computer software (treatment control module 54) which assists a user to plan for, execute, and review the results of a medical treatment procedure, as will be discussed in more detail below. For example, the treatment control module 54 assists a user to plan for a medical treatment procedure by enabling a user to more accurately position each of the probes 22 of the pulse generator 10 in relation to the lesion 300 in a way that will generate the most effective treatment zone. The treatment control module 54 can display the anticipated treatment zone based on the position of the probes and the treatment parameters. The treatment control module 54 can display the progress of the treatment in real time and can display the results of the treatment procedure after it is completed. This information can be used to determine whether the treatment was successful and whether it is necessary to re-treat the patient.
For purposes of this application, the terms “code”, “software”, “program”, “application”, “software code”, “software module”, “module” and “software program” are used interchangeably to mean software instructions that are executable by a processor.
The “user” can be a physician or other medical professional. The treatment control module 54 executed by a processor outputs various data including text and graphical data to the monitor 11 associated with the generator 10.
Referring now to
In one embodiment, the computer 40 is built into the voltage generator 10. In another embodiment, the computer 40 is a separate unit which is connected to the voltage generator through the communication link 52. In a preferred embodiment, the communication link 52 is a USB link.
In one embodiment, the imaging device 30 is a stand alone device which is not connected to the computer 40. In the embodiment as shown in
The basic functionality of the computer software (treatment control module 54) will now be discussed in relation to the following example.
It should be noted that the software can be used independently of the generator 10. For example, the user can plan the treatment in a different computer as will be explained below and then save the treatment parameters to an external memory device, such as a USB flash drive (not shown). The data from the memory device relating to the treatment parameters can then be downloaded into the computer 40 to be used with the generator 10 for treatment.
After the treatment control module 54 is initialized, it displays an “Information” screen with various input boxes as shown in
The dimensions of the lesion 300 are determined from viewing it on the monitor 31 of the imaging device 30 (see
In the embodiment shown in
The user can select the “ECG synchronization” option by clicking the circle in the box 110 in order to synchronize the pulses with an electrocardiogram (ECG) device, if such a device is being used during the procedure. The other options available for treatment that are included in box 110 can include an option for “90 PPM” (pulses per minute) or “240 PPM”. The user should select at least one of the three options provided in box 110. After all of the necessary data has been inputted, the user clicks on the “Next” button with a pointing device 14 to proceed to the next screen described below.
Further regarding the ECG synchronization option, if this circle is selected in window 110, the treatment control module 54 will test this functionality to verify that the system is working properly. The treatment control module 54 can automatically detect whether an error has occurred during the testing phase of the ECG feature. The detectable errors include, but are not limited to, “no signal” (such as no pulses for 3.5 seconds) and “noisy” (such as pulses occurring at a rate greater than 120 beats per minute for at least 3.5 seconds).
The treatment control module 54 can synchronize energy release with cardiac rhythm by analyzing cardiac output such as electrocardiogram results (or other cardiac function output) and sending synchronization signals to a controller of the pulse generator 10. The control module 54 is also capable of generating internal flags such as a synchronization problem flag and a synchronization condition flag to indicate to users on a graphic user interface a synchronization status, so that energy pulse delivery can be synchronized with the cardiac rhythm for each beat (in real-time) or aborted as necessary for patient safety and treatment efficiency.
Specifically, the control module 54 synchronizes energy pulses such as IRE (irreversible electroporation) pulses with a specific portion of the cardiac rhythm. The module uses the R-wave of the heartbeat and generates a control signal to the pulse generator 10 indicating that this portion of the heartbeat is optimal for release of IRE pulses. For clarity, the S wave would be an optimal time for delivery of an energy pulse, but due to the fact that the S wave ends nebulously in some cases, the R wave is used as an indicator to start timing of energy release.
More specifically, the synchronization feature of the control module 54 allows for monitoring of heart signals so as to ensure that changes, maladies, and other alterations associated with the heartbeat are coordinated such that pulses from the pulse generator 10 are released at the proper time, and that if the heartbeat is out of its normal rhythm, that the release of energy is either altered or aborted.
Next, the user can select the number of probes that the user believes will be necessary to produce a treatment zone which will adequately cover the lesion 300 and any safety margin 301. The selection is made by clicking the circle next to each type of device, as shown in the “Probe Selection” screen, illustrated in
In one embodiment, a “Probes Selection Status” box 199 identifies which of the receptacles, if any, on the generator 10 have been connected to a probe by displaying the phrase “Connected” or the like next to the corresponding probe number. In one embodiment, each receptacle includes an RFID device and a connector for each probe which connects to the receptacle and includes a compatible RFID device, so that the treatment control module 54 can detect whether or not an authorized probe has been connected to the receptacle on the generator 10 by detecting a connection of the compatible RFID devices. If an authorized probe is not connected to a receptacle on the generator, the phrase “Not Connected” or the like will appear next to the probe number. In addition, the color of each probe shown in the “Probes Selection Status” box 199 can be used to indicate whether or not each receptacle on the generator is connected to a compatible probe. This feature allows the user to verify that the requisite number of probes are properly connected to the generator 10 before selecting a probe type for the treatment procedure. For example, if the treatment control module 54 detects a problem with the probe connection status (e.g. selecting a three probe array when only two probes are connected to the generator), it can notify the user by displaying an error message.
The user can select which of the connected probes will be used to perform the treatment procedure, by clicking on the box next to the selected probes in the “Probes Selection Status” box 199. By default the treatment control module 54 will automatically select probes in ascending numerical order, as they are labeled.
Referring to
The amount of longitudinal exposure of the active electrode portion for each probe that has already been manually adjusted by the user as explained above can be manually inputted in input box 210, which can be selected by the user according to the depth (z) of the lesion. In this way, the treatment control module 54 can generate an estimated treatment zone according to the treatment parameters, and locations and depths of the probes. In one embodiment, a second x-z grid is displayed on the monitor 11 of the computer running the treatment control module 54. In one embodiment, the treatment control module 54 can automatically calculate preferred values for the amount of longitudinal exposure of the active electrode portions based on the size and shape of the lesion. The depth (z) of the electric field image can be calculated analytically or with interpolation and displayed on the x-z grid. Because the distribution of the electric field (i.e., expected treatment region) between two monopolar electrodes may “dip in” along the boundary line (e.g., a peanut shaped treatment region due to large spacing between the two electrodes where the width of the region is smaller in the middle; see for example region 305 in
The probe dock status is indicated in box 210, by indicating if the probes are “docked” or “undocked”. The “UnDock Probes” button allows the user to “unplug” the probes from the generator while the “Probe Placement Process” screen is displayed without causing error messages. In normal operation, the user plugs the probes into the generator on the “Probe Selection” screen, and then the probes are “authorized” as being compatible probes according to the RFID devices, as discussed above. When the user proceeds to the “Probe Placement Process” screen, the software requires that all the selected probes remain plugged into the generator, or else the software will display an error message (e.g. “Probe #2 unplugged”, etc.), and will also force the user back to the “Probe Selection” screen. However, sometimes doctors may want to perform another scan of the lesion or perform some other procedure while leaving the probes inserted in the patient. But, if the procedure cannot be performed near the generator, the probes are unplugged from the generator. If the user selects the “UnDock Probes” button, this will allow the probes to be unplugged from the generator without causing an error message. Then, after the user has performed the other procedure that was required, he can re-attach the probes to the generator, and then select “Dock Probes” in input box 210. In this way, the user will not receive any error messages while the “Probe Placement Process” screen is displayed.
There is a default electric field density setting (Volts/cm) which is shown in input box 211. In the example, the default setting is 1500 Volts/cm. This number represents the electric field density that the user believes is needed to effectively treat the cells, e.g., ablate the tissue cells. For example, 1500 Volts/cm is an electric field density that is needed to irreversibly electroporate the tissue cells. Based on the number selected in input box 211, the treatment control module 54 automatically adjusts the voltage (treatment energy level) applied between the electrodes, as shown in column 222.
Box 280 allows a user to select between two different Volts/cm types, namely “Linear” or “Non-Linear Lookup”.
The default Volts/cm setting is “Linear”, in which case the Voltage that is applied between a given pair of electrodes, as shown in column 222, is determined by the following formula:
Voltage=xd, (1)
If the user selects “Non-Linear Lookup” in box 280, then the Voltage that is applied between the given pair of electrodes will be similar to the Voltage values for a “Linear” selection when a pair of electrodes are closely spaced together (e.g. within about 1 cm). However, as a pair of given electrodes are spaced farther from one another, a “Non-Linear Lookup” will produce lower Voltages between the given pair of electrodes as compared to the Voltage values for a “Linear” selection at any given distance. The “Non-Linear Lookup” feature is particularly useful for reducing “popping” during treatment. “Popping” refers to an audible popping noise that sometimes occurs, which is believed to be caused by a plasma discharge from high voltage gradients at the tip of the electrodes. The “Non-Linear Lookup” feature can also minimize any swelling of the tissue that might occur as a result of a treatment. The Voltage values used for the “Non-Linear Lookup” selection can be pre-determined based on animal experiments and other research. In one embodiment, different tissue types can each have their own “Non-Linear Lookup” table. In the example shown, the tissue being treated is prostate tissue.
The details of the treatment parameters are displayed in window 270. The firing (switching) sequence between probes is listed automatically in window 270. In the example, the firing sequence involves six steps beginning with between probes 1 and 2, then probes 1 and 3, then probes 2 and 3, then probes 2 and 4, then probes 3 and 4, and then probes 4 and 1. As shown, the polarity of each of the probes may switch from negative to positive according to step of the firing sequence. Column 220 displays which probe is the positive probe (according to a number assigned to each probe) for each step. Column 221 displays which probe is the negative probe (according to a number assigned to each probe) for each step. Column 222 displays the actual voltage generated between each probe during each step of the firing sequence. In the example, the maximum voltage that can be generated between probes is limited by the capabilities of the generator 10, which in the example is limited to a maximum of 3000 Volts. Column 223 displays the length of each pulse that is generated between probes during each respective step of the firing sequence. In the example, the pulse length is predetermined and is the same for each respective step, and is set at 100 microseconds. Column 224 displays the number of pulses that is generated during each respective step of the firing sequence. In the example, the number of pulses is predetermined and is the same for each respective step, and is set at 90 pulses which are applied in a set of 10 pulses at a time. Column 225 displays the setting for Volts/cm according to the value selected at input box 211. Column 226 displays the actual distance between the electrodes (measured in cm), which is automatically calculated according to the placement of each probe in the grid 200.
The treatment control module 54 can be programmed to calculate and display the area of the combined treatment regions on the grid 200 by several different methods.
Each method determines a boundary line surrounding a treatment zone that is created between a pair of electrodes. By combining a plurality of treatment zones with each treatment zone being defined by a pair of electrodes, a combined treatment region can be displayed on the x-y grid.
As discussed above, the monitor can further include an x-z grid to illustrate the depth of the lesion and the shape of the treatment region. The shape of the treatment zone in the x-z grid will vary according to the selected amounts of electrode exposure for each probe and can be determined by one or more methods.
In one embodiment, the treatment boundary line that is created between two points on the x-y grid can be rotated about an axis joining the two points in order to generate the treatment region boundary line on the x-z grid. In this embodiment, several points may be selected along the exposed length of the active electrode portion for each probe at various depths (z). A three-dimensional combined treatment region can then be generated by determining the boundary line on the x-y grid between each individual pair of points and then rotating the boundary line along the axis joining each pair of points. The resulting boundary lines can be combined to create a three dimensional image that is displayed on the monitor.
The following is an alternate method for determining a boundary line on the x-z grid, thereby determining a three dimensional treatment region. This example describes a two probe array with the probes being inserted in a parallel relationship and with the probes having the same amount of exposed portions of the electrode. In this example, the exposed portions of each probe start at the same “uppermost” depth (z) and end at the same “lowermost” depth (z). First, a treatment zone boundary line is created in the x-y plane at the uppermost depth (z). Next, the treatment zone boundary line is repeatedly created stepwise for all subsequently lower depths (z), preferably evenly spaced, until the lowermost depth (z) is reached. The result is a 3-D volume (stacked set of treatment zone boundary lines) having a flat top surface and a flat bottom surface. Next, two new focus points are selected, with the first focus point positioned midway between the probe positions in the x-y grid and near the uppermost depth (z) of the exposed electrode. The second focus point is also positioned midway between the probe positions in the x-y grid, but near the lowermost depth (z) of the exposed electrode. Next, a treatment zone boundary line is created in the x-z grid using one of the methods described earlier. The actual placement of each focus point may be closer together, namely, not positioned in the uppermost and lowermost x-y planes defined by the exposed portions. The placement of each focus point should be selected so that the treatment zone boundary line that is created in the x-z grid closely matches the treatment zone boundary lines that were created in the uppermost and lowermost x-y grids. Next, the treatment zone boundary line that was created in the x-z grid according to the two focus points is rotated about the axis joining the two focus points. This creates the shapes for the upper and lower 3-D volumes which are added to the flat top surface and the flat bottom surface described above.
The above methods can be applied by persons of ordinary skill in the art to create 3-D treatment zones between exposed portions of electrodes even when the probes are not parallel to each other and even when the amount of the exposed portion varies with each probe.
Furthermore, there are situations where it is advantageous to show multiple boundary zones as a result of a therapy. For example, indicating which regimes undergo no change, reversible electroporation, irreversible electroporation, and conventional thermal damage is possible in accordance with the present invention. In addition, it is possible to output the entire distribution rather than just delineating boundaries.
It has been shown repeatedly in the literature that tissue properties are highly variable between tissue types, between individuals, and even within an individual. These changes may result from differences in body fat composition, hydration levels, and hormone cycles. Due to the large dependence of IRE (irreversible electroporation) treatments on tissue conductivity, it is imperative to have accurate values. Therefore, to obtain viable conductivity values prior to treatment, a low amplitude voltage pulse is used between the electrode conductors and the resultant impedance/conductance is measured as a way to determine pertinent tissue property data such as the predicted current. The value determined may then be implemented when assessing field strength and treatment protocol in real time. For example, the resulting impedance or predicted current can be used to set the default electric field density.
One method of generating an estimated treatment region between a pair of treatment electrodes is a numerical model based method involving finite element analysis (FEA). For example, U.S. Patent Application Publication No. 2007/0043345, which is hereby incorporated by reference, discloses using FEA models to generate treatment zones between a pair of electrodes (the calculations were performed using MATLAB's finite element solver, Femlab v2.2 (The MathWorks, Inc. Natick, Mass.)).
Most engineering problems can be solved by breaking the system into cells where each corner of the cell or mesh is a node. FEA is used to relate each node to each of the other nodes by applying sets of partial differential equations. This type of a system can be coded by scratch, but most people use one of many commercial FEA programs that automatically define the mesh and create the equations given the model geometry and boundary conditions. Some FEA programs only work in one area of engineering, for example, heat transfer and others are known as multiphysics. These systems can convert electricity to heat and can be used for studying the relationships between different types of energy.
Typically the FEA mesh is not homogeneous and areas of transition have increased mesh density. The time and resources (memory) required to solve the FEA problem are proportional to the number of nodes, so it is generally unwise to have a uniformly small mesh over the entire model. If possible, FEA users also try to limit the analysis to 2D problems and/or use planes of symmetry to limit the size of the model being considered because even a modest 2D model often requires 30 minutes to several hours to run. By comparison, a 3D Model usually takes several hours to several days to run. A complicated model like a weather system or a crash simulation may take a super computer several days to complete.
Depending on the complexity of the FEA models that are required, the purchase price of the FEA modeling software can cost several thousand dollars for a low end system to $30 k for a non linear multiphysics system. The systems that model the weather are custom made and cost tens of millions of dollars.
In one example, the steps which are required for generating a treatment zone between a pair of treatment probes using finite element analysis include: (1) creating the geometry of interest (e.g., a plane of tissue with two circular electrodes); (2) defining the materials involved (e.g., tissue, metal); (3) defining the boundary conditions (e.g., Initial voltage, Initial temperature); (4) defining the system load (e.g., change the voltage of the electrodes to 3,000V); (5) determining the type of solver that will be used; (6) determining whether to use a time response or steady state solution; (7) running the model and wait for the analysis to finish; and (8) displaying the results.
Using FEA, however, may not be practical for use in calculating and displaying in real time a treatment zone that is created between a pair of treatment probes in accordance with the present invention because of the time required to run these types of analyses. For the present invention, the system should allow a user to experiment with probe placement and should calculate a new treatment zone in less than a few seconds. Accordingly, the FEA model is not appropriate for such use and it would be desirable to find an analytic solution (closed form solution), which can calculate the treatment zones with only simple equations, but which closely approximate the solutions from a numerical model analysis such as the finite element analysis. The closed loop solutions should preferably generate the treatment zone calculation in a fraction of a second so as to allow a physician/user to experiment with probe placement in real time.
There are different closed loop (analytical model analysis) methods for estimating and displaying a treatment zone between a pair of treatment probes, which produce similar results to what would have been derived by a numerical model analysis such as FEA, but without the expense and time of performing FEA. Analytical models are mathematical models that have a closed form solution, i.e., the solution to the equations used to describe changes in a system can be expressed as a mathematical analytic function. The following method represents just one of the non-limiting examples of such alternative closed loop solutions.
In mathematics, a Cassini oval is a set (or locus) of points in the plane such that each point p on the oval bears a special relation to two other fixed points q1 and q2: the product of the distance from p to q1 and the distance from p to q2 is constant. That is, if the function dist(x,y) is defined to be the distance from a point x to a point y, then all points p on a Cassini oval satisfy the equation:
dist(q1,p)×dist(q2,p)=b2 (2)
The points q1 and q2 are called the foci of the oval.
Suppose q1 is the point (a,0), and q2 is the point (−a,0). Then the points on the curve satisfy the equation:
((x−a)2+y2)((x+a)2+y2)=b4 (3)
The Equivalent Polar Equation is:
r4−2a2r2 cos 2θ=b4−a4 (4)
The shape of the oval depends on the ratio b/a. When b/a is greater than 1, the locus is a single, connected loop. When b/a is less than 1, the locus comprises two disconnected loops. When b/a is equal to 1, the locus is a lemniscate of Bernoulli.
The Cassini equation provides a very efficient algorithm for plotting the boundary line of the treatment zone that was created between two probes on the grid 200. By taking pairs of probes for each firing sequence, the first probe is set as q1 being the point (a,0) and the second probe is set as q2 being the point (−a, 0).
The polar equation for the Cassini curve is preferably used because it provides a more efficient equation for computation. The current algorithm can work equally as well by using the Cartesian equation of the Cassini curve. By solving for r2 from eq. (4) above, the following polar equation was developed:
r2=a2 cos(2*theta)+/−sqrt(b4−a4 sin2(2*theta)) (5)
As can be seen from the mathematics involved in the equation, r can be up to four separate values for each given value for theta.
If V=2495 Volts; a=0.7 cm; and A=650 V/cm;
Then b2=1.376377
A portion of the solutions for eq. (5) are shown in Table 1 below:
The above eq. (6) was developed according to the following analysis.
The curve from the cassini oval equation was calibrated as best as possible to the 650 V/cm contour line using two 1-mm diameter electrodes with an electrode spacing between 0.5-5 cm and an arbitrary applied voltage.
For this worksheet, q1 and q2 reference points (taken to be +/−electrodes) could be moved to locations along the x-axis to points of (±a,0). A voltage could then be selected, and an arbitrary scaling factor (“gain denominator”) would convert this voltage to the corresponding “b” used in eq. (4). The worksheet would then plot the resulting Cassini oval, which has a shape progression with applied voltage beginning as two circles around the electrodes that grow into irregular ellipses before converging into a single “peanut” shape that ultimately becomes an ellipse expanding from the original electrode locations.
The Cassini oval creates a reasonable visualization that mimics the shape of numerical results for the field distribution. In order to understand which values or levels correspond to a desired electric field of interest, a calibration involving the b4 term was necessary to develop the relationship between the analytical Cassini oval and the numerical results. This was done through a backwards calibration process defined as follows:
Table 1 incorporates all the steps above to yield a single, calibrated Cassini Oval output that analytically predicts the electric field distribution; providing a quick and simple solution for the prediction of IRE (irreversible electroporation) treatment regions that may be adjusted in real-time. The inputs are the electrode location (as a given “±a” distance from the origin along the x-axis), the applied voltage to the energized electrode, and the desired electric field to visualize. The resulting output is a contour representing a threshold where the entire area within it has been subjected to an electric field the one selected; and thus treated by IRE. It is important to remember that the analytical solution was calibrated for an electric field contour of 650 V/cm, and thus yields an accurate approximation for this value. Other field strength contours of interest still yield reasonable results that mimic the overall shape of the electric field. Overall, the analytical solution provided yields consistently good predictions for electric field strengths, and thus, treatment regions of IRE that may be used during treatment planning or analysis.
A similar algorithm for calibration can be used for a bipolar electrode.
In one example, the diameter of the probe is 0.065 cm, and the lengths of the two electrodes are respectively 0.295 cm and 0.276 cm, separated by an insulation sleeve of 0.315 cm in length. Adapting this scenario to the cassini oval presents some challenges because the distribution is now resulting from the two exposed cylinder lengths, rather than two distinct loci of points. This was solved by calibrating individual electric field contours for the same applied voltage and developing two equations that adjust the separation distance (±a) and gain denominator (GD) according to the equations:
a=710−9*E3−2*10−5*E2+0.015*E+6.1619;R2=0.9806 (8)
GD=1.0121*E+1920;R2=0.9928 (9)
The treatment control module 54 can further include a feature that tracks the treatment progress and provides the user with an option to automatically retreat for low or missing pulses, or over-current pulses (see discussion below). Also, if the generator stops prematurely for any reason, the treatment control module 54 can restart at the same point where it terminated, and administer the missing treatment pulses as part of the same treatment.
In other embodiments, the treatment control module 54 is able to detect certain errors during treatment, which include, but are not limited to, “charge failure”, “hardware failure”, “high current failure”, and “low current failure”.
According to the present invention, irreversible electroporation (IRE) ablation (n=81, where n is the number of IRE ablation procedures) was performed in-vivo in 22 pig livers using 2-4 IRE electrodes (18 gauge, 2 cm long tip) and a NanoKnife™ generator (AngioDynamics, Fremont, CA) as described in the IRE Treatment Application referenced above and as shown in
Multiple variables for energy deposition and electrode configuration were studied including: inter-electrode spacing (1.5 cm-3 cm); the number of IRE pulses applied between electrode pairs (c=10, 50, & 100); and the order and number of times/cycles each electrode pair was activated.
For c=10, a sequence of delivered pulses are as follows: 10 sequential IRE pulses were delivered per electrode pair for all pairs (e.g., 10 pulses for pair 1-2, then 10 pulses for pair 2-3 and then 10 pulses for pair 3-1 for a 3-electrode array). Then the same sequence is repeated 2 to 44 times for a total number of IRE pulses delivered of 20 to 440 per electrode pair. Electrode phase (polarity) was changed after each sequence (1-2, 2-3, 3-1; 2-1, 3-2, 1-3), which reduces gas buildup near the electrodes to thereby reduce the chance of sparks. In one experiment, a total of 90 IRE pulses were delivered for each electrode pair.
For c=50, a sequence of 50 IRE pulses were delivered per electrode pair for all pairs. Then the same sequence is repeated one more time for a total number of IRE pulses delivered of 100 per electrode pair.
For c=100, a sequence of 100 sequential IRE pulses were delivered per each electrode pair. Then the same sequence is repeated one more time for a total number of IRE pulses delivered of 200 per electrode pair.
Between two pulses, two electrode pairs and two sequences, there is a waiting (delay) period. The reasons for the waiting period are to dissipate any thermal buildup in the tissue cells, especially around the electrodes where the current density is highest, and to increase the ablation zone.
Preferably, the generator 10 inserts a time delay between two pulses (inter-pulse delay) of at least 250 ms (milliseconds) and at most 15 seconds, and more preferably at least 1 second and at most 8 seconds. At greater than 8 seconds, the ablation zone does not increase and actually may help to decrease it.
Preferably, the generator 10 inserts a time delay of 5 seconds to 10 minutes between electrode pairs (inter-pair delay) within a sequence. Preferably, the generator inserts a time delay of 5 seconds to 20 minutes between two sequences (inter-sequence delay).
With a single IRE pulse, the cells try to close the holes/pores created in the membrane within a fraction of a second. By applying multiple pulses with inter-pulse, inter-pair and inter-sequence delays, it is believed that the cells' attempt to repeatedly close the holes exhaust their ability to close them, which thereby increases the ablation zone.
Ablations were performed under ultrasound guidance. Dimensions of resultant zones of treatment were measured by ultrasound 1-3 hr post-procedure and confirmed at gross and histopathology. These data and ablation times were compared and subject to statistical analysis to determine optimal pulse parameters.
Although the experiments involved 10, 50 and 100 pulses in a sequence, the general inventive concept can be expanded to include as little as 1 pulse per electrode pair in a sequence. In other words, for a 3 electrode array, a sequence of 1 IRE pulse per electrode pair is applied for all three pairs. Then, the sequence is repeated for 70 to 100 times. Preferably, the number of pulses for each electrode pair in a single sequence can vary between 1 and 280.
Currently, the NanoKnife generator is programmed to deliver a single IRE pulse per cardiac cycle if a cardiac-sync is selected. In a 3 or more multi-electrode array, more than one IRE pulse per cycle can be delivered by switching electrodes using the switch 74. For example, in a 3 electrode-array arrangement, in a single cardiac cycle, a sequence of single IRE pulse between pair 1-2, between pair 2-3 and between pair 2-3 can be applied for a total of 3 IRE pulses delivered, for example, within an R-wave of the cycle.
Alternatively, for applying 100 pulses, a sequence of 10 IRE pulses between pair 1-2, then between pair 2-3 and then between pair 2-3 can be applied for a total of 10 sets to deliver a total of 100 pulses for each electrode pair. For applying 500 pulses, a sequence of 10 IRE pulses can be sequentially applied to the 3 electrode pairs for a total of 50 sets. For applying 1000 pulses, a sequence of 10 IRE pulses can be sequentially applied to the 3 electrode pairs for a total of 100 sets.
The IRE pulses can be unipolar pulses or alternating polarity pulses such as biphasic pulses or consecutive positive and negative pulses separated by a slight time delay.
According to the experiments, the largest contiguous zones of treatment effect (6.4±0.6 cm width and length, 3.7±1.4 cm height) were achieved applying 2 cycles (sequences) of 50 IRE pulses sequentially to all electrode pairs within a 4 electrode array of 2.5 cm spacing (total time=17.5±6.7 min). For 4 electrode arrays, treatment diameter best correlated with overall time of the energy application [r2=0.71]). Greatest ablation for 3 electrode arrays (5.9±0.4 cm×5.3±0.5 cm cross-sectional area) was achieved by continuously delivering 10 pulses sequentially to each of the 3 electrode pairs for 10-12 min. For 2 electrode arrays using similar energy application strategies, ablation of only 3.9±0.5 cm length with variable width (incomplete to 2.4 cm) was achieved.
In another experiment, IRE ablation procedures were performed on porcine liver using the following parameters: 2.5 cm spacing between the electrodes, 100 μs pulses, 3 kVolts, 2 cm exposed electrodes, and 100-1000 pulses delivered.
As can be seen, there is generally a positive correlation between the number of pulses (and therefore the total pulse application time) and the size of the ablation region although the rate of increase slows as more pulses are applied. For length, it varied between 4 cm and 5.7. For width, it varied between 1.5 cm and 3.3 cm. Using a curve fitting algorithm, the graph for length and width produced the following formulas:
y=1.6832*x−0.1849, where x=length in centimeter, and
y=0.3407*x−0.3381, where x=width in centimeter.
Table 2 below summarizes the experimental data in terms of the increase in size in two dimensions (area) and three dimensions (volume).
As seen above, for two dimensional regions, increasing the number of pulses from 100 to 600 and 1000 respectively produced a surprisingly large increase of 166% and 230% in ablation area. If an assumption is made that the increase in depth is similar to the increase in length, then increasing the number of pulses from 100 to 600 and 1000 respectively produces an increase of 266% and 395% in ablation volume.
Based on the above relationship between the ablation size and the number of delivered pulses, calculation of the estimated treatment region can be adjusted accordingly. For example, if the experimental data show that the shape of the treatment region increases proportionally (width, length and depth of the region), then the term b{circumflex over ( )}2 in the Cassini oval equation may be adjusted accordingly. If, however, the shape of the treatment region increases in a non-proportional manner (e.g., length increases at twice the rate as the width), then the Cassini oval equation can be modified by adding or subtracting a constant to the b{circumflex over ( )}2 term (e.g., b{circumflex over ( )}2+/−C) as well as adjusting the b{circumflex over ( )}2 term itself. Alternatively, the number of electrodes can be reduced.
Aside from varying the number of applied pulses, varying the width of each pulse from 20 microseconds to 100 microseconds produced a slight increase in the ablation size. Increasing the pulse width, however, also reduced the variance in ablation size (i.e., reduction in standard deviation). As the pulse width increased past 50-70 microseconds, the variance among the ablation sizes decreased substantially. This effect became more pronounced for longer spacing between the electrodes (e.g., greater than 3 cm). Thus, this information could also be used to increase the ablation size and also to more accurately predict the ablation size.
In procedures involving 3 or more electrodes, rather than applying the total number of electrodes sequentially for each pair, then moving on to the next pair, dividing up the total number of pulses to be delivered into smaller subsets and then applying each subset of pulses to each pair, and then repeating the sequence for the subsequent subsets while reversing the polarity for each sequence (i.e., E1(+)−E2(−), then E2(+)−E1(−) in the next sequence) produced an increase in the ablation size, especially when the total number of pulses for each pair was substantially higher than 100.
For a 3-electrode procedure and the total number of pulses=500, for example, the sequence of delivered pulses are as follows: 10 sequential IRE pulses per electrode pair for all pairs (e.g., 10 pulses for pair 1-2, then 10 pulses for pair 2-3 and then 10 pulses for pair 3-1). Then the same sequence is repeated 50 times for a total number of IRE pulses delivered of 500 per electrode pair with the electrode phase (polarity) being reversed after each sequence.
However, according to the present invention, the enlarged target region 301 can be adequately covered by an increased ablation area 325 which has been calculated based on 1000 pulses (and which has been superimposed over the target region 301). Since such a large treatment area 325 can damage too much of good tissue, after receiving identification of a target region, the treatment control module 54 can select/adjust the number of pulses or number of electrodes, or both so that the resulting estimated treatment area sufficiently covers the target region 301 while minimizing ablation of good tissue. One way to do so is to generate a plurality of estimated ablation regions based on a plurality of pulse count, and then selecting the minimum pulse count that completely covers the target region 301 while minimizing damage to good tissue.
Advantageously, the present invention allows treatment of larger ablation regions with fewer electrodes to thereby provide a safer and less expensive electrical ablation procedure for patients. The present invention also allows treatment of a larger ablation area without dividing up the area into multiple regions and repeating the procedure.
The above disclosure is intended to be illustrative and not exhaustive. This description will suggest many modifications, variations, and alternatives may be made by ordinary skill in this art without departing from the scope of the invention. Those familiar with the art may recognize other equivalents to the specific embodiments described herein. Accordingly, the scope of the invention is not limited to the foregoing specification.
This application is a Continuation of U.S. Non-Provisional application Ser. No. 15/612,006, filed Jun. 2, 2017, which is a Continuation of U.S. Non-Provisional application Ser. No. 13/273,001, now U.S. Pat. No. 9,700,368, filed Oct. 13, 2011, which claims the benefit of U.S. Provisional Application No. 61/392,905, filed Oct. 13, 2010, all of which is incorporated by reference herein. This application is also related to PCT International Application Number PCT/US10/29243, filed Mar. 30, 2010 and entitled “System and Method for Estimating a Treatment Region for a Medical Treatment Device and for Interactively Planning a Treatment of a Patient” (hereinafter the “IRE Treatment Application”), which is incorporated herein by reference. This application is also related to PCT International Application Number PCT/US10/36734, filed May 28, 2010 and entitled “System and Method for Synchronizing Energy Delivery to the Cardiac Rhythm”, which is also incorporated herein by reference.
Number | Name | Date | Kind |
---|---|---|---|
1329496 | Binkley | Feb 1920 | A |
1351661 | Kaufman | Aug 1920 | A |
1376652 | Steedman | May 1921 | A |
1380272 | Tomasulo | May 1921 | A |
1430015 | Icher | Sep 1922 | A |
1437941 | Hoover | Dec 1922 | A |
1442697 | Orthmann | Jan 1923 | A |
1443360 | Grace | Jan 1923 | A |
1445198 | Bornmann | Feb 1923 | A |
1450391 | Shaw | Apr 1923 | A |
3437941 | Leary | Apr 1969 | A |
3634460 | Nelson | Jan 1972 | A |
3639545 | Wilcox | Feb 1972 | A |
3730238 | Butler | May 1973 | A |
3746004 | Jankelson | Jul 1973 | A |
3871359 | Pacela | Mar 1975 | A |
4016866 | Lawton | Apr 1977 | A |
4037341 | Odle | Jul 1977 | A |
4216860 | Heimann | Aug 1980 | A |
4224949 | Scott | Sep 1980 | A |
4267047 | Henne | May 1981 | A |
4278092 | Borsanyi et al. | Jul 1981 | A |
4299217 | Sagae et al. | Nov 1981 | A |
4304239 | Perlin | Dec 1981 | A |
4311148 | Courtney | Jan 1982 | A |
4336881 | Babb et al. | Jun 1982 | A |
4344436 | Kubota | Aug 1982 | A |
4392855 | Oreopoulos | Jul 1983 | A |
4406827 | Carim | Sep 1983 | A |
4416276 | Newton et al. | Nov 1983 | A |
4447235 | Clarke | May 1984 | A |
4469098 | Davi | Sep 1984 | A |
4489535 | Veltman | Dec 1984 | A |
4512765 | Muto | Apr 1985 | A |
4580572 | Granek | Apr 1986 | A |
4636199 | Victor | Jan 1987 | A |
4672969 | Dew | Jun 1987 | A |
4676258 | Inokuchi | Jun 1987 | A |
4676782 | Yamamoto | Jun 1987 | A |
4687471 | Twardowski | Aug 1987 | A |
4716896 | Ackerman | Jan 1988 | A |
4723549 | Wholey | Feb 1988 | A |
D294519 | Hardy, Jr. | Mar 1988 | S |
4756838 | Veltman | Jul 1988 | A |
4772269 | Twardowski | Sep 1988 | A |
4798585 | Inoue | Jan 1989 | A |
4813929 | Semrad | Mar 1989 | A |
4819637 | Dormandy, Jr. | Apr 1989 | A |
4822470 | Chang | Apr 1989 | A |
4836204 | Landymore | Jun 1989 | A |
4840172 | Augustine | Jun 1989 | A |
4863426 | Ferragamo | Sep 1989 | A |
4885003 | Hillstead | Dec 1989 | A |
4886496 | Conoscenti | Dec 1989 | A |
4886502 | Poirier et al. | Dec 1989 | A |
4889634 | El-Rashidy | Dec 1989 | A |
4903707 | Knute | Feb 1990 | A |
4919148 | Muccio | Apr 1990 | A |
4921484 | Muccio | Apr 1990 | A |
4920978 | Colvin | May 1990 | A |
4976709 | Sand | Dec 1990 | A |
4981477 | Schon | Jan 1991 | A |
4986810 | Semrad | Jan 1991 | A |
4987895 | Heimlich | Jan 1991 | A |
5031775 | Kane | Jul 1991 | A |
5053013 | Ensminger | Oct 1991 | A |
5071558 | Itob | Dec 1991 | A |
5122137 | Lennox | Jun 1992 | A |
5137517 | Loney | Aug 1992 | A |
5141499 | Zappacosta | Aug 1992 | A |
D329496 | Wotton | Sep 1992 | S |
5156597 | Verreet | Oct 1992 | A |
5186715 | Phillips | Feb 1993 | A |
5186800 | Dower | Feb 1993 | A |
5188592 | Hakki | Feb 1993 | A |
5190541 | Abele | Mar 1993 | A |
5192312 | Orton | Mar 1993 | A |
5209723 | Twardowski et al. | May 1993 | A |
5215530 | Hogan | Jun 1993 | A |
5222997 | Montgomery | Jun 1993 | A |
5224933 | Bromander | Jul 1993 | A |
5227730 | King | Jul 1993 | A |
5242415 | Kantrowitz et al. | Sep 1993 | A |
D343687 | Houghton, II | Jan 1994 | S |
5277201 | Stern | Jan 1994 | A |
5279564 | Taylor | Jan 1994 | A |
5281213 | Milder | Jan 1994 | A |
5290263 | Wigness et al. | Mar 1994 | A |
5308325 | Quinn et al. | May 1994 | A |
5308338 | Helfrich | May 1994 | A |
5318543 | Ross | Jun 1994 | A |
5334167 | Cocanower | Aug 1994 | A |
5348554 | Imran | Sep 1994 | A |
D351661 | Fischer | Oct 1994 | S |
5383917 | Desai | Jan 1995 | A |
5391158 | Peters | Feb 1995 | A |
5405320 | Twardowski et al. | Apr 1995 | A |
5417687 | Nardella | May 1995 | A |
5424752 | Yamazaki | Jun 1995 | A |
5439444 | Andersen | Aug 1995 | A |
5458597 | Edwards | Oct 1995 | A |
5462521 | Brucker | Oct 1995 | A |
5462644 | Woodson | Oct 1995 | A |
5484400 | Edwards | Jan 1996 | A |
5484401 | Rodriguez | Jan 1996 | A |
5536267 | Edwards | Jul 1996 | A |
5540737 | Fenn | Jul 1996 | A |
5542916 | Hirsch | Aug 1996 | A |
5546940 | Panescu et al. | Aug 1996 | A |
5562720 | Stern et al. | Oct 1996 | A |
D376652 | Hunt | Dec 1996 | S |
5582588 | Sakurai et al. | Dec 1996 | A |
5586982 | Abela | Dec 1996 | A |
5588424 | Insler | Dec 1996 | A |
5588960 | Edwards et al. | Dec 1996 | A |
5599294 | Edwards | Feb 1997 | A |
5599311 | Raulerson | Feb 1997 | A |
5616126 | Malekmehr | Apr 1997 | A |
5620479 | Diederich | Apr 1997 | A |
5630426 | Eggers et al. | May 1997 | A |
D380272 | Partika | Jun 1997 | S |
5643197 | Brucker | Jul 1997 | A |
5645855 | Lorenz | Jul 1997 | A |
5653684 | Laptewicz | Aug 1997 | A |
5672173 | Gough | Sep 1997 | A |
5672174 | Gough | Sep 1997 | A |
5681282 | Eggers | Oct 1997 | A |
5683384 | Gough et al. | Nov 1997 | A |
5687723 | Avitall | Nov 1997 | A |
5690620 | Knott | Nov 1997 | A |
5697905 | D Ambrosio | Dec 1997 | A |
5700252 | Klingenstein | Dec 1997 | A |
5707332 | Weinberger | Jan 1998 | A |
5718246 | Vona | Feb 1998 | A |
5728143 | Gough | Mar 1998 | A |
5735847 | Gough et al. | Apr 1998 | A |
5749914 | Janssen | May 1998 | A |
5752939 | Makoto | May 1998 | A |
5782827 | Gough et al. | Jul 1998 | A |
5800484 | Gough et al. | Sep 1998 | A |
5807272 | Kun et al. | Sep 1998 | A |
5807306 | Shapland | Sep 1998 | A |
5807395 | Mulier | Sep 1998 | A |
5810742 | Pearlman | Sep 1998 | A |
5810804 | Gough | Sep 1998 | A |
5830184 | Basta | Nov 1998 | A |
5836897 | Sakurai et al. | Nov 1998 | A |
5843182 | Goldstein | Dec 1998 | A |
5856081 | Fahy | Jan 1999 | A |
5863290 | Gough et al. | Jan 1999 | A |
5865787 | Shapland et al. | Feb 1999 | A |
5866756 | Giros et al. | Feb 1999 | A |
5868708 | Hart | Feb 1999 | A |
5873877 | McGaffigan | Feb 1999 | A |
5904648 | Arndt et al. | May 1999 | A |
5913855 | Gough et al. | Jun 1999 | A |
5919191 | Lennox et al. | Jul 1999 | A |
5921982 | Lesh | Jul 1999 | A |
5944710 | Dev et al. | Aug 1999 | A |
5947284 | Foster | Sep 1999 | A |
5951546 | Lorentzen | Sep 1999 | A |
5954745 | Gertler | Sep 1999 | A |
5957919 | Laufer | Sep 1999 | A |
5957963 | Dobak, III | Sep 1999 | A |
5968006 | Hofmann | Oct 1999 | A |
5983140 | Smith | Nov 1999 | A |
5984896 | Boyd | Nov 1999 | A |
5993466 | Yoon | Nov 1999 | A |
6004339 | Wijay | Dec 1999 | A |
6009647 | Feingold | Jan 2000 | A |
6009877 | Edwards | Jan 2000 | A |
6010452 | Harcourt | Jan 2000 | A |
6010616 | Lewis | Jan 2000 | A |
6012885 | Taylor | Jan 2000 | A |
6023638 | Swanson | Feb 2000 | A |
6029090 | Herbst | Feb 2000 | A |
6033402 | Tu | Mar 2000 | A |
6043066 | Mangano | Mar 2000 | A |
6050994 | Sherman | Apr 2000 | A |
6055456 | Gerber | Apr 2000 | A |
6059780 | Gough | May 2000 | A |
6066134 | Eggers et al. | May 2000 | A |
6068121 | McGlinch | May 2000 | A |
6071281 | Burnside | Jun 2000 | A |
6074374 | Fulton | Jun 2000 | A |
6074389 | Levine et al. | Jun 2000 | A |
6090016 | Kuo | Jul 2000 | A |
6090105 | Zepeda et al. | Jul 2000 | A |
D430015 | Himbert | Aug 2000 | S |
6096035 | Sodhi | Aug 2000 | A |
6106524 | Eggers et al. | Aug 2000 | A |
6110192 | Ravenscroft et al. | Aug 2000 | A |
6113593 | Tu | Sep 2000 | A |
6116330 | Salyer | Sep 2000 | A |
6120493 | Hofmann | Sep 2000 | A |
6123701 | Nezhat | Sep 2000 | A |
6132397 | Davis et al. | Oct 2000 | A |
6134460 | Chance | Oct 2000 | A |
6135999 | Fanton | Oct 2000 | A |
6139544 | Mikus | Oct 2000 | A |
6139545 | Utley et al. | Oct 2000 | A |
6142992 | Cheng | Nov 2000 | A |
6150148 | Nanda | Nov 2000 | A |
6152923 | Ryan | Nov 2000 | A |
6178354 | Gibson | Jan 2001 | B1 |
D437941 | Frattini | Feb 2001 | S |
6193715 | Wrublewski et al. | Feb 2001 | B1 |
6198970 | Freed | Mar 2001 | B1 |
6200314 | Sherman | Mar 2001 | B1 |
D442697 | Hajianpour | May 2001 | S |
6233490 | Kasevich | May 2001 | B1 |
6235023 | Lee | May 2001 | B1 |
D443360 | Haberland | Jun 2001 | S |
6241725 | Cosman | Jun 2001 | B1 |
D445198 | Frattini | Jul 2001 | S |
6258100 | Alferness | Jul 2001 | B1 |
6258249 | Simpson | Jul 2001 | B1 |
6277114 | Bullivant et al. | Aug 2001 | B1 |
6280441 | Ryan | Aug 2001 | B1 |
6283988 | Laufer | Sep 2001 | B1 |
6283989 | Laufer | Sep 2001 | B1 |
6284140 | Sommermeyer | Sep 2001 | B1 |
6287293 | Jones et al. | Sep 2001 | B1 |
6287304 | Eggers et al. | Sep 2001 | B1 |
6296636 | Cheng | Oct 2001 | B1 |
6298726 | Adachi | Oct 2001 | B1 |
6299633 | Laufer | Oct 2001 | B1 |
D450391 | Hunt | Nov 2001 | S |
6312428 | Eggers | Nov 2001 | B1 |
6327505 | Medhkour | Dec 2001 | B1 |
6328689 | Gonzalez et al. | Dec 2001 | B1 |
6328735 | Curley | Dec 2001 | B1 |
6330478 | Lee | Dec 2001 | B1 |
6375634 | Carroll | Apr 2002 | B1 |
6398779 | Buysse | Jun 2002 | B1 |
6403347 | Bills | Jun 2002 | B1 |
6405732 | Edwards | Jun 2002 | B1 |
6411852 | Danek | Jun 2002 | B1 |
6419674 | Bowser | Jul 2002 | B1 |
6428802 | Atala | Aug 2002 | B1 |
6437551 | Krulevitch | Aug 2002 | B1 |
6443952 | Mulier et al. | Sep 2002 | B1 |
6463331 | Edwards | Oct 2002 | B1 |
6478793 | Cosman | Nov 2002 | B1 |
6482221 | Hebert et al. | Nov 2002 | B1 |
6485487 | Sherman | Nov 2002 | B1 |
6488673 | Laufer | Dec 2002 | B1 |
6488678 | Sherman | Dec 2002 | B2 |
6488680 | Francischelli et al. | Dec 2002 | B1 |
6491706 | Alferness | Dec 2002 | B1 |
6493569 | Foo | Dec 2002 | B2 |
6493589 | Medhkour | Dec 2002 | B1 |
6497704 | Ein-Gal | Dec 2002 | B2 |
6503248 | Levine | Jan 2003 | B1 |
6506189 | Rittman, III et al. | Jan 2003 | B1 |
6514248 | Eggers et al. | Feb 2003 | B1 |
6520183 | Amar | Feb 2003 | B2 |
D471640 | McMichael | Mar 2003 | S |
D471641 | McMichael | Mar 2003 | S |
6533784 | Truckai | Mar 2003 | B2 |
6537976 | Gupta | Mar 2003 | B1 |
6540695 | Burbank | Apr 2003 | B1 |
6558378 | Sherman | May 2003 | B2 |
6569162 | He | May 2003 | B2 |
6575967 | Leveen | Jun 2003 | B1 |
6575969 | Rittman, III | Jun 2003 | B1 |
6589161 | Corcoran | Jul 2003 | B2 |
6589174 | Chopra et al. | Jul 2003 | B1 |
6592594 | Rimbaugh | Jul 2003 | B2 |
6610054 | Edwards | Aug 2003 | B1 |
6616657 | Simpson | Sep 2003 | B2 |
D480816 | McMichael | Oct 2003 | S |
6634363 | Danek et al. | Oct 2003 | B1 |
6638253 | Breznock | Oct 2003 | B2 |
6638275 | McGaffigan | Oct 2003 | B1 |
6666858 | Lafontaine | Dec 2003 | B2 |
6673070 | Edwards et al. | Jan 2004 | B2 |
6678558 | Dimmer et al. | Jan 2004 | B1 |
6682501 | Nelson | Jan 2004 | B1 |
6689096 | Loubens et al. | Feb 2004 | B1 |
6689127 | Gough et al. | Feb 2004 | B1 |
6694170 | Mikus | Feb 2004 | B1 |
6694964 | Wu | Feb 2004 | B2 |
6694979 | Deem | Feb 2004 | B2 |
6694984 | Habib | Feb 2004 | B2 |
6695861 | Rosenberg | Feb 2004 | B1 |
6712811 | Underwood | Mar 2004 | B2 |
D489973 | Root | May 2004 | S |
6733516 | Simons | May 2004 | B2 |
6753171 | Karube | Jun 2004 | B2 |
6761716 | Kadhiresan | Jul 2004 | B2 |
6770070 | Balbierz | Aug 2004 | B1 |
D495807 | Agbodoe | Sep 2004 | S |
6812204 | McHale | Nov 2004 | B1 |
6837886 | Collins | Jan 2005 | B2 |
6847848 | Sterzer | Jan 2005 | B2 |
6860847 | Alferness | Mar 2005 | B2 |
6869430 | Balbierz | Mar 2005 | B2 |
6881213 | Ryan | Apr 2005 | B2 |
6895267 | Panescu | May 2005 | B2 |
6905480 | McGuckin, Jr. | Jun 2005 | B2 |
6926713 | Rioux | Aug 2005 | B2 |
6941950 | Wilson | Sep 2005 | B2 |
6942681 | Johnson | Sep 2005 | B2 |
6958062 | Gough | Oct 2005 | B1 |
6960189 | Bates | Nov 2005 | B2 |
6972013 | Zhang | Dec 2005 | B1 |
6989010 | Francischelli | Jan 2006 | B2 |
6994689 | Zadno-Azizi | Feb 2006 | B1 |
7008421 | Daniel | Mar 2006 | B2 |
7011094 | Rapacki | Mar 2006 | B2 |
7012061 | Reiss | Mar 2006 | B1 |
7027869 | Danek | Apr 2006 | B2 |
7036510 | Zgoda | May 2006 | B2 |
7054665 | Turner | May 2006 | B2 |
7054685 | Dimmer | May 2006 | B2 |
7087040 | McGuckin, Jr. | Aug 2006 | B2 |
7097612 | Bertolero | Aug 2006 | B2 |
7100616 | Springmeyer | Sep 2006 | B2 |
7113821 | Sun | Sep 2006 | B1 |
7162303 | Levin | Jan 2007 | B2 |
7169107 | Jersey-Willuhn | Jan 2007 | B2 |
7232437 | Berman | Jun 2007 | B2 |
7250048 | Francischelli | Jul 2007 | B2 |
D549332 | Matsumoto | Aug 2007 | S |
7257450 | Auth | Aug 2007 | B2 |
7264002 | Danek | Sep 2007 | B2 |
7273055 | Danek | Sep 2007 | B2 |
7291146 | Steinke | Nov 2007 | B2 |
7331940 | Sommerich | Feb 2008 | B2 |
7331949 | Marisi | Feb 2008 | B2 |
7341558 | De La Torre | Mar 2008 | B2 |
7344533 | Pearson | Mar 2008 | B2 |
D565743 | Phillips | Apr 2008 | S |
D571478 | Horacek | Jun 2008 | S |
7387626 | Edwards | Jun 2008 | B2 |
7399747 | Clair | Jul 2008 | B1 |
D575399 | Matsumoto | Aug 2008 | S |
D575402 | Sandor | Aug 2008 | S |
7412977 | Fields | Aug 2008 | B2 |
7419487 | Johnson | Sep 2008 | B2 |
7434578 | Dillard | Oct 2008 | B2 |
7437194 | Skwarek | Oct 2008 | B2 |
7449019 | Uchida | Nov 2008 | B2 |
7451765 | Adler | Nov 2008 | B2 |
7455675 | Schur | Nov 2008 | B2 |
7476203 | Devore | Jan 2009 | B2 |
7488292 | Adachi | Feb 2009 | B2 |
7520877 | Lee, Jr. | Apr 2009 | B2 |
7533671 | Gonzalez | May 2009 | B2 |
D595422 | Mustapha | Jun 2009 | S |
7544301 | Shah | Jun 2009 | B2 |
7549984 | Mathis | Jun 2009 | B2 |
7553309 | Buysse | Jun 2009 | B2 |
7565208 | Harris | Jul 2009 | B2 |
7571729 | Saadat | Aug 2009 | B2 |
7617005 | Demarais | Nov 2009 | B2 |
7620451 | Demarais | Nov 2009 | B2 |
7620507 | Richardson | Nov 2009 | B2 |
7632291 | Stephens | Dec 2009 | B2 |
7647115 | Levin | Jan 2010 | B2 |
7653438 | Deem | Jan 2010 | B2 |
7655004 | Long | Feb 2010 | B2 |
7670333 | Schatzberger | Mar 2010 | B2 |
7674249 | Ivorra | Mar 2010 | B2 |
7680543 | Azure | Mar 2010 | B2 |
D613418 | Ryan | Apr 2010 | S |
7699842 | Buysse | Apr 2010 | B2 |
7706865 | Snell | Apr 2010 | B1 |
7717948 | Demarais | May 2010 | B2 |
7718409 | Rubinsky | May 2010 | B2 |
7722606 | Azure | May 2010 | B2 |
7742795 | Stone | Jun 2010 | B2 |
7763018 | Decarlo | Jul 2010 | B2 |
7765010 | Chornenky | Jul 2010 | B2 |
7771401 | Hekmat | Aug 2010 | B2 |
7776035 | Rick | Aug 2010 | B2 |
7815571 | Deckman | Oct 2010 | B2 |
7815662 | Spivey | Oct 2010 | B2 |
7824870 | Kovalcheck | Nov 2010 | B2 |
RE42016 | Chornenky et al. | Dec 2010 | E |
7846108 | Turovskiy | Dec 2010 | B2 |
7853333 | Demarais | Dec 2010 | B2 |
D630321 | Hamilton, Jr. | Jan 2011 | S |
D631154 | Hamilton, Jr. | Jan 2011 | S |
7874986 | Deckman | Jan 2011 | B2 |
7875025 | Cockburn | Jan 2011 | B2 |
7879031 | Peterson | Feb 2011 | B2 |
RE42277 | Jaafar et al. | Apr 2011 | E |
7918852 | Tullis | Apr 2011 | B2 |
7937143 | Demarais | May 2011 | B2 |
7938824 | Chornenky | May 2011 | B2 |
7951582 | Gazit | May 2011 | B2 |
7955827 | Rubinsky | Jun 2011 | B2 |
RE42835 | Chornenky | Oct 2011 | E |
D647628 | Helfteren | Oct 2011 | S |
8029504 | Long | Oct 2011 | B2 |
8037591 | Spivey | Oct 2011 | B2 |
8048067 | Davalos | Nov 2011 | B2 |
8052604 | Lau | Nov 2011 | B2 |
8057391 | Lau | Nov 2011 | B2 |
8062290 | Buysse | Nov 2011 | B2 |
RE43009 | Chornenky | Dec 2011 | E |
8070759 | Stefanchik | Dec 2011 | B2 |
8075572 | Stefanchik | Dec 2011 | B2 |
8088072 | Munrow | Jan 2012 | B2 |
8100922 | Griffith | Jan 2012 | B2 |
8109926 | Azure | Feb 2012 | B2 |
8114070 | Rubinsky | Feb 2012 | B2 |
8114072 | Long | Feb 2012 | B2 |
8114119 | Spivey | Feb 2012 | B2 |
8131371 | Demarals | Mar 2012 | B2 |
8131372 | Levin | Mar 2012 | B2 |
8145316 | Deem | Mar 2012 | B2 |
8145317 | Demarais | Mar 2012 | B2 |
8150518 | Levin | Apr 2012 | B2 |
8150519 | Demarais | Apr 2012 | B2 |
8150520 | Demarais | Apr 2012 | B2 |
8154288 | Deimling | Apr 2012 | B2 |
8157834 | Conlon | Apr 2012 | B2 |
8162918 | Ivorra | Apr 2012 | B2 |
8172772 | Zwolinski | May 2012 | B2 |
8174267 | Brannan | May 2012 | B2 |
8175711 | Demarais | May 2012 | B2 |
8180433 | Brannan | May 2012 | B2 |
8181995 | Decarlo | May 2012 | B2 |
8182477 | Orszulak | May 2012 | B2 |
8187269 | Shadduck | May 2012 | B2 |
8187270 | Auth | May 2012 | B2 |
8206300 | Deckman | Jun 2012 | B2 |
8211097 | Leyh | Jul 2012 | B2 |
8211099 | Buysse | Jul 2012 | B2 |
8211125 | Spivey | Jul 2012 | B2 |
8216161 | Darlington | Jul 2012 | B2 |
8221411 | Francischelli | Jul 2012 | B2 |
8231603 | Hobbs | Jul 2012 | B2 |
8240468 | Wilkinson | Aug 2012 | B2 |
8241204 | Spivey | Aug 2012 | B2 |
8242782 | Brannan | Aug 2012 | B2 |
8246615 | Behnke | Aug 2012 | B2 |
8248075 | Brannan | Aug 2012 | B2 |
8251986 | Chornenky | Aug 2012 | B2 |
8252057 | Fox | Aug 2012 | B2 |
8262563 | Bakos | Sep 2012 | B2 |
8262577 | Munrow | Sep 2012 | B2 |
8262655 | Ghabrial | Sep 2012 | B2 |
8262680 | Swain | Sep 2012 | B2 |
8267884 | Hicks | Sep 2012 | B1 |
8267927 | Dalal | Sep 2012 | B2 |
8267936 | Hushka | Sep 2012 | B2 |
8277379 | Lau | Oct 2012 | B2 |
8282631 | Davalos | Oct 2012 | B2 |
8287527 | Brannan | Oct 2012 | B2 |
8292880 | Prakash | Oct 2012 | B2 |
8298222 | Rubinsky | Oct 2012 | B2 |
8303516 | Schmitz | Nov 2012 | B2 |
8317806 | Coe | Nov 2012 | B2 |
8337394 | Vakharia | Dec 2012 | B2 |
8343144 | Kleyman | Jan 2013 | B2 |
8346370 | Haley | Jan 2013 | B2 |
8347891 | Demarais | Jan 2013 | B2 |
8348921 | Ivorra | Jan 2013 | B2 |
8348938 | Blomgren | Jan 2013 | B2 |
8353487 | Trusty | Jan 2013 | B2 |
8353902 | Prakash | Jan 2013 | B2 |
8361006 | Kraemer | Jan 2013 | B2 |
8361066 | Long | Jan 2013 | B2 |
8361112 | Carroll, II | Jan 2013 | B2 |
8366712 | Bleich | Feb 2013 | B2 |
8377057 | Rick | Feb 2013 | B2 |
8380283 | Krieg | Feb 2013 | B2 |
D677798 | Hart | Mar 2013 | S |
8394092 | Brannan | Mar 2013 | B2 |
8394102 | Garabedian | Mar 2013 | B2 |
8398626 | Buysse | Mar 2013 | B2 |
8398641 | Wallace | Mar 2013 | B2 |
8403924 | Behnke | Mar 2013 | B2 |
8403926 | Nobis | Mar 2013 | B2 |
8409200 | Holcomb | Apr 2013 | B2 |
8409206 | Wallace | Apr 2013 | B2 |
8417328 | Sarfaty | Apr 2013 | B2 |
8425455 | Nentwick | Apr 2013 | B2 |
8425505 | Long | Apr 2013 | B2 |
8433423 | Demarais | Apr 2013 | B2 |
8437845 | Sarfaty | May 2013 | B2 |
8439907 | Auth | May 2013 | B2 |
8444640 | Demarais | May 2013 | B2 |
8449538 | Long | May 2013 | B2 |
8454594 | Demarais | Jun 2013 | B2 |
8465464 | Travis | Jun 2013 | B2 |
8465484 | Davalos | Jun 2013 | B2 |
8469716 | Fedotov | Jun 2013 | B2 |
8473067 | Hastings | Jun 2013 | B2 |
8480657 | Bakos | Jul 2013 | B2 |
8480665 | Decarlo | Jul 2013 | B2 |
8480666 | Buysse | Jul 2013 | B2 |
8480689 | Spivey | Jul 2013 | B2 |
8489192 | Hlavka | Jul 2013 | B1 |
8496574 | Trusty | Jul 2013 | B2 |
8506485 | Deckman | Aug 2013 | B2 |
8506564 | Long | Aug 2013 | B2 |
8511317 | Thapliyal | Aug 2013 | B2 |
8512329 | Paulus | Aug 2013 | B2 |
8512330 | Epstein | Aug 2013 | B2 |
8518031 | Boyden | Aug 2013 | B2 |
8529563 | Long | Sep 2013 | B2 |
8542019 | Brannan | Sep 2013 | B2 |
8546979 | Heeren | Oct 2013 | B2 |
8548600 | Deem | Oct 2013 | B2 |
8551069 | Demarais | Oct 2013 | B2 |
8551088 | Falkenstein | Oct 2013 | B2 |
8551097 | Schmitz | Oct 2013 | B2 |
8562588 | Hobbs | Oct 2013 | B2 |
8562598 | Falkenstein | Oct 2013 | B2 |
8562599 | Leyh | Oct 2013 | B2 |
8562602 | Azure | Oct 2013 | B2 |
8568401 | Brannan | Oct 2013 | B2 |
8568402 | Buysse | Oct 2013 | B2 |
8568404 | Brannan | Oct 2013 | B2 |
8568410 | Vakharia | Oct 2013 | B2 |
8568411 | Falkenstein | Oct 2013 | B2 |
8579894 | Falkenstein | Nov 2013 | B2 |
8579897 | Vakharia | Nov 2013 | B2 |
8579902 | Bleich | Nov 2013 | B2 |
8585704 | Schmitz | Nov 2013 | B2 |
8603087 | Rubinsky | Dec 2013 | B2 |
8608652 | Voegele | Dec 2013 | B2 |
8608739 | Sartor | Dec 2013 | B2 |
8613745 | Bleich | Dec 2013 | B2 |
8617163 | Bleich | Dec 2013 | B2 |
8620423 | Demarais | Dec 2013 | B2 |
8626300 | Demarais | Jan 2014 | B2 |
8632534 | Pearson | Jan 2014 | B2 |
8634929 | Chornenky | Jan 2014 | B2 |
8647338 | Chornenky | Feb 2014 | B2 |
8647346 | Bleich | Feb 2014 | B2 |
8652130 | Kreindel | Feb 2014 | B2 |
8652138 | Bleich | Feb 2014 | B2 |
8652150 | Swain | Feb 2014 | B2 |
8663210 | Tomasello | Mar 2014 | B2 |
8663228 | Schmitz | Mar 2014 | B2 |
8668688 | Rusin | Mar 2014 | B2 |
8672937 | Decarlo | Mar 2014 | B2 |
8679003 | Spivey | Mar 2014 | B2 |
8684998 | Demarais | Apr 2014 | B2 |
8702697 | Curley | Apr 2014 | B2 |
8706258 | Nabors, Sr. | Apr 2014 | B2 |
8712500 | Schmidt | Apr 2014 | B2 |
8715276 | Thompson | May 2014 | B2 |
8721637 | Zarins | May 2014 | B2 |
8725249 | Bar-Yoseph | May 2014 | B2 |
8728137 | Zarins | May 2014 | B2 |
8728138 | Zarins | May 2014 | B2 |
8728139 | Azure | May 2014 | B2 |
8731672 | Hlavka | May 2014 | B2 |
8740895 | Mayse | Jun 2014 | B2 |
8740896 | Zarins | Jun 2014 | B2 |
8753335 | Moshe | Jun 2014 | B2 |
8768470 | Deem | Jul 2014 | B2 |
8771252 | Gelfand | Jul 2014 | B2 |
8771260 | Conlon | Jul 2014 | B2 |
8774913 | Demarais | Jul 2014 | B2 |
8774922 | Zarins | Jul 2014 | B2 |
8777943 | Mayse | Jul 2014 | B2 |
8784463 | Zarins | Jul 2014 | B2 |
8797039 | Brannan | Aug 2014 | B2 |
8801626 | Sun | Aug 2014 | B2 |
8805545 | Zarins | Aug 2014 | B2 |
8808280 | Mayse | Aug 2014 | B2 |
8814860 | Davalos | Aug 2014 | B2 |
8818514 | Zarins | Aug 2014 | B2 |
8821489 | Mayse | Sep 2014 | B2 |
8828031 | Fox | Sep 2014 | B2 |
8835166 | Phillips | Sep 2014 | B2 |
8845559 | Darlington | Sep 2014 | B2 |
8845629 | Demarais | Sep 2014 | B2 |
8845635 | Daniel | Sep 2014 | B2 |
8845639 | Wallace | Sep 2014 | B2 |
8852163 | Deem | Oct 2014 | B2 |
8858550 | Busch-Madsen | Oct 2014 | B2 |
8865076 | Sarfaty | Oct 2014 | B2 |
8880185 | Hastings | Nov 2014 | B2 |
8880186 | Levin | Nov 2014 | B2 |
8880195 | Azure | Nov 2014 | B2 |
8882759 | Manley | Nov 2014 | B2 |
8888792 | Harris | Nov 2014 | B2 |
8894641 | Brannan | Nov 2014 | B2 |
8903488 | Callas | Dec 2014 | B2 |
8906006 | Chornenky | Dec 2014 | B2 |
8906011 | Gelbart | Dec 2014 | B2 |
8906035 | Zwolinski | Dec 2014 | B2 |
8911439 | Mayse | Dec 2014 | B2 |
8915910 | Falkenstein | Dec 2014 | B2 |
8915911 | Azure | Dec 2014 | B2 |
8920411 | Gelbart | Dec 2014 | B2 |
8923970 | Bar-Yoseph | Dec 2014 | B2 |
8926606 | Davalos | Jan 2015 | B2 |
8932287 | Gelbart | Jan 2015 | B2 |
8932289 | Mayse | Jan 2015 | B2 |
8934978 | Deem | Jan 2015 | B2 |
8939897 | Nobis | Jan 2015 | B2 |
8939970 | Stone | Jan 2015 | B2 |
8945121 | Curley | Feb 2015 | B2 |
8948865 | Zarins | Feb 2015 | B2 |
8956350 | Buysse | Feb 2015 | B2 |
8958871 | Demarais | Feb 2015 | B2 |
8958888 | Chornenky | Feb 2015 | B2 |
8961507 | Mayse | Feb 2015 | B2 |
8961508 | Mayse | Feb 2015 | B2 |
8968542 | Davalos | Mar 2015 | B2 |
8974451 | Smith | Mar 2015 | B2 |
8983595 | Levin | Mar 2015 | B2 |
8986294 | Demarais | Mar 2015 | B2 |
8992517 | Davalos | Mar 2015 | B2 |
9005189 | Davalos | Apr 2015 | B2 |
9005195 | Mayse | Apr 2015 | B2 |
9005198 | Long | Apr 2015 | B2 |
9011431 | Long | Apr 2015 | B2 |
9017323 | Miller | Apr 2015 | B2 |
9017324 | Mayse | Apr 2015 | B2 |
9023034 | Jenson | May 2015 | B2 |
9023037 | Zarins | May 2015 | B2 |
9028483 | Long | May 2015 | B2 |
9028485 | Edmunds | May 2015 | B2 |
9039702 | Miller | May 2015 | B2 |
9049987 | Conlon | Jun 2015 | B2 |
9050449 | Darlington | Jun 2015 | B2 |
9060761 | Hastings | Jun 2015 | B2 |
9072518 | Swanson | Jul 2015 | B2 |
9072527 | Deem | Jul 2015 | B2 |
9078665 | Moss | Jul 2015 | B2 |
9084609 | Smith | Jul 2015 | B2 |
9089350 | Willard | Jul 2015 | B2 |
9101386 | Wallace | Aug 2015 | B2 |
9108040 | Zarins | Aug 2015 | B2 |
9113888 | Orszulak | Aug 2015 | B2 |
9119633 | Gelbart | Sep 2015 | B2 |
9119634 | Gelbart | Sep 2015 | B2 |
9125643 | Hlavka | Sep 2015 | B2 |
9125661 | Deem | Sep 2015 | B2 |
9125666 | Steinke | Sep 2015 | B2 |
9125667 | Stone | Sep 2015 | B2 |
9131978 | Zarins | Sep 2015 | B2 |
9138281 | Zarins | Sep 2015 | B2 |
9138287 | Curley | Sep 2015 | B2 |
9138288 | Curley | Sep 2015 | B2 |
9149328 | Dimmer | Oct 2015 | B2 |
9149331 | Deem | Oct 2015 | B2 |
9155589 | Jenson | Oct 2015 | B2 |
9173704 | Hobbs | Nov 2015 | B2 |
9186198 | Demarais | Nov 2015 | B2 |
9186209 | Weber | Nov 2015 | B2 |
9186213 | Deem | Nov 2015 | B2 |
9192435 | Jenson | Nov 2015 | B2 |
9192715 | Gelfand | Nov 2015 | B2 |
9192790 | Hastings | Nov 2015 | B2 |
9198733 | Neal, II | Dec 2015 | B2 |
9220526 | Conlon | Dec 2015 | B2 |
9220558 | Willard | Dec 2015 | B2 |
9220561 | Crow | Dec 2015 | B2 |
9226772 | Fox | Jan 2016 | B2 |
9226790 | Zemel | Jan 2016 | B2 |
9233241 | Long | Jan 2016 | B2 |
9247952 | Bleich | Feb 2016 | B2 |
9248318 | Darlington | Feb 2016 | B2 |
9254169 | Long | Feb 2016 | B2 |
9254172 | Behnke, II | Feb 2016 | B2 |
9265557 | Sherman | Feb 2016 | B2 |
9265558 | Zarins | Feb 2016 | B2 |
9276367 | Brannan | Mar 2016 | B2 |
9277955 | Herscher | Mar 2016 | B2 |
9277969 | Brannan | Mar 2016 | B2 |
9283051 | Garcia | Mar 2016 | B2 |
9289255 | Deem | Mar 2016 | B2 |
9295516 | Pearson | Mar 2016 | B2 |
9307935 | Pluta | Apr 2016 | B2 |
9308039 | Azure | Apr 2016 | B2 |
9308043 | Zarins | Apr 2016 | B2 |
9308044 | Zarins | Apr 2016 | B2 |
9314620 | Long | Apr 2016 | B2 |
9314630 | Levin | Apr 2016 | B2 |
9320561 | Zarins | Apr 2016 | B2 |
9320563 | Brustad | Apr 2016 | B2 |
9326751 | Hastings | May 2016 | B2 |
9326817 | Zarins | May 2016 | B2 |
9327100 | Perry | May 2016 | B2 |
9327122 | Zarins | May 2016 | B2 |
9339618 | Deem | May 2016 | B2 |
9351790 | Zemel | May 2016 | B2 |
9414881 | Callas | Aug 2016 | B2 |
9598691 | Davalos | Mar 2017 | B2 |
9700368 | Callas | Jul 2017 | B2 |
9764145 | Callas | Sep 2017 | B2 |
9867652 | Sano | Jan 2018 | B2 |
9943599 | Gehl | Apr 2018 | B2 |
10010666 | Rubinsky | Jul 2018 | B2 |
10117701 | Davalos | Nov 2018 | B2 |
10117707 | Garcia | Nov 2018 | B2 |
10143512 | Rubinsky | Dec 2018 | B2 |
10154874 | Davalos | Dec 2018 | B2 |
10238447 | Neal, II | Mar 2019 | B2 |
10245098 | Davalos | Apr 2019 | B2 |
10245105 | Davalos | Apr 2019 | B2 |
10272178 | Davalos | Apr 2019 | B2 |
10286108 | Davalos | May 2019 | B2 |
10292755 | Arena | May 2019 | B2 |
10342600 | Callas | Jul 2019 | B2 |
10448989 | Arena | Oct 2019 | B2 |
10470822 | Garcia | Nov 2019 | B2 |
10471254 | Sano | Nov 2019 | B2 |
10537379 | Sano | Jan 2020 | B2 |
10668208 | Rubinsky | Jun 2020 | B2 |
10694972 | Davalos | Jun 2020 | B2 |
10702326 | Neal, II | Jul 2020 | B2 |
10828085 | Davalos | Nov 2020 | B2 |
10828086 | Davalos | Nov 2020 | B2 |
10905492 | Neal, II | Feb 2021 | B2 |
10959772 | Davalos | Mar 2021 | B2 |
11254926 | Neal, II | Feb 2022 | B2 |
11272979 | Garcia | Mar 2022 | B2 |
11311329 | Davalos | Apr 2022 | B2 |
11382681 | Arena | Jul 2022 | B2 |
11406820 | Sano | Aug 2022 | B2 |
11453873 | Davalos | Sep 2022 | B2 |
11607271 | Garcia | Mar 2023 | B2 |
11607537 | Latouche | Mar 2023 | B2 |
11638603 | Sano | May 2023 | B2 |
11655466 | Neal, II | May 2023 | B2 |
11737810 | Davalos | Aug 2023 | B2 |
20010014819 | Ingle | Aug 2001 | A1 |
20010039393 | Mori | Nov 2001 | A1 |
20010043706 | Masuda | Nov 2001 | A1 |
20010046706 | Rubinsky | Nov 2001 | A1 |
20010047167 | Heggeness | Nov 2001 | A1 |
20010051366 | Rubinsky | Dec 2001 | A1 |
20020002393 | Mitchell | Jan 2002 | A1 |
20020022864 | Mahvi | Feb 2002 | A1 |
20020040204 | Dev | Apr 2002 | A1 |
20020049370 | Laufer | Apr 2002 | A1 |
20020052601 | Goldberg | May 2002 | A1 |
20020065541 | Fredricks | May 2002 | A1 |
20020072742 | Schaefer | Jun 2002 | A1 |
20020077314 | Falk | Jun 2002 | A1 |
20020077627 | Johnson | Jun 2002 | A1 |
20020082543 | Park | Jun 2002 | A1 |
20020091362 | Maginot | Jul 2002 | A1 |
20020095197 | Lardo | Jul 2002 | A1 |
20020104318 | Jaafar | Aug 2002 | A1 |
20020111615 | Cosman | Aug 2002 | A1 |
20020112729 | Devore | Aug 2002 | A1 |
20020115208 | Mitchell | Aug 2002 | A1 |
20020119437 | Grooms | Aug 2002 | A1 |
20020120261 | Morris | Aug 2002 | A1 |
20020133324 | Weaver | Sep 2002 | A1 |
20020137121 | Rubinsky | Sep 2002 | A1 |
20020138075 | Edwards | Sep 2002 | A1 |
20020143365 | Herbst | Oct 2002 | A1 |
20020147462 | Mair | Oct 2002 | A1 |
20020156472 | Lee | Oct 2002 | A1 |
20020161361 | Sherman | Oct 2002 | A1 |
20020183684 | Dev | Dec 2002 | A1 |
20020183735 | Edwards | Dec 2002 | A1 |
20020183740 | Edwards | Dec 2002 | A1 |
20020188242 | Wu | Dec 2002 | A1 |
20020193784 | McHale | Dec 2002 | A1 |
20030009165 | Edwards | Jan 2003 | A1 |
20030014047 | Woloszko | Jan 2003 | A1 |
20030016168 | Jandrell | Jan 2003 | A1 |
20030055220 | Legrain | Mar 2003 | A1 |
20030059945 | Dzekunov | Mar 2003 | A1 |
20030074039 | Puskas | Apr 2003 | A1 |
20030078490 | Damasco | Apr 2003 | A1 |
20030088199 | Kawaji | May 2003 | A1 |
20030096407 | Atala | May 2003 | A1 |
20030105454 | Cucin | Jun 2003 | A1 |
20030109871 | Johnson | Jun 2003 | A1 |
20030127090 | Gifford | Jul 2003 | A1 |
20030135242 | Mongeon | Jul 2003 | A1 |
20030149451 | Chomenky | Aug 2003 | A1 |
20030153960 | Chornenky | Aug 2003 | A1 |
20030154988 | Devore | Aug 2003 | A1 |
20030159700 | Laufer | Aug 2003 | A1 |
20030164168 | Shaw | Sep 2003 | A1 |
20030166181 | Rubinsky | Sep 2003 | A1 |
20030194808 | Rubinsky | Oct 2003 | A1 |
20030195385 | Devore | Oct 2003 | A1 |
20030195406 | Jenkins | Oct 2003 | A1 |
20030199050 | Mangano | Oct 2003 | A1 |
20030208236 | Heil | Nov 2003 | A1 |
20030212394 | Pearson | Nov 2003 | A1 |
20030212412 | Dillard | Nov 2003 | A1 |
20030228344 | Fields | Dec 2003 | A1 |
20030233091 | Whayne | Dec 2003 | A1 |
20040009459 | Anderson | Jan 2004 | A1 |
20040055606 | Hendricksen | Mar 2004 | A1 |
20040059328 | Daniel | Mar 2004 | A1 |
20040068228 | Cunningham | Apr 2004 | A1 |
20040116935 | Lechot | Jun 2004 | A1 |
20040116965 | Falkenberg | Jun 2004 | A1 |
20040133194 | Eum | Jul 2004 | A1 |
20040138715 | Van Groeningen | Jul 2004 | A1 |
20040167458 | Draghia-Akli | Aug 2004 | A1 |
20040172136 | Ralph | Sep 2004 | A1 |
20040176855 | Badylak | Sep 2004 | A1 |
20040187875 | He | Sep 2004 | A1 |
20040193042 | Scampini | Sep 2004 | A1 |
20040193097 | Hofmann | Sep 2004 | A1 |
20040199159 | Lee | Oct 2004 | A1 |
20040200484 | Springmeyer | Oct 2004 | A1 |
20040206349 | Alferness | Oct 2004 | A1 |
20040210248 | Gordon | Oct 2004 | A1 |
20040236376 | Miklavcic | Nov 2004 | A1 |
20040237340 | Rembrandt | Dec 2004 | A1 |
20040267256 | Garabedian | Dec 2004 | A1 |
20040267340 | Cioanta | Dec 2004 | A1 |
20050004507 | Schroeppel | Jan 2005 | A1 |
20050010209 | Lee | Jan 2005 | A1 |
20050010259 | Gerber | Jan 2005 | A1 |
20050013726 | Hill | Jan 2005 | A1 |
20050013870 | Freyman | Jan 2005 | A1 |
20050019830 | Penner | Jan 2005 | A1 |
20050020965 | Rioux | Jan 2005 | A1 |
20050033276 | Adachi | Feb 2005 | A1 |
20050048651 | Ryttsen | Mar 2005 | A1 |
20050054978 | Segal | Mar 2005 | A1 |
20050061322 | Freitag | Mar 2005 | A1 |
20050063974 | Reinhard | Mar 2005 | A1 |
20050066974 | Fields | Mar 2005 | A1 |
20050096537 | Parel | May 2005 | A1 |
20050096709 | Skwarek | May 2005 | A1 |
20050107781 | Ostrovsky | May 2005 | A1 |
20050112141 | Terman | May 2005 | A1 |
20050135393 | Benco | Jun 2005 | A1 |
20050143817 | Hunter | Jun 2005 | A1 |
20050171522 | Christopherson | Aug 2005 | A1 |
20050171571 | Goodin | Aug 2005 | A1 |
20050197619 | Rule | Sep 2005 | A1 |
20050203489 | Saadat | Sep 2005 | A1 |
20050216047 | Kumoyama | Sep 2005 | A1 |
20050228373 | Kelly | Oct 2005 | A1 |
20050228459 | Levin | Oct 2005 | A1 |
20050228460 | Levin | Oct 2005 | A1 |
20050234445 | Conquergood | Oct 2005 | A1 |
20050234523 | Levin | Oct 2005 | A1 |
20050261707 | Schatzberger | Nov 2005 | A1 |
20050267407 | Goldman | Dec 2005 | A1 |
20050282284 | Rubinsky | Dec 2005 | A1 |
20050283149 | Thorne | Dec 2005 | A1 |
20050288684 | Aronson | Dec 2005 | A1 |
20050288702 | McGurk | Dec 2005 | A1 |
20060004356 | Bilski | Jan 2006 | A1 |
20060004400 | McGurk | Jan 2006 | A1 |
20060009748 | Mathis | Jan 2006 | A1 |
20060020347 | Barrett | Jan 2006 | A1 |
20060024359 | Walker | Feb 2006 | A1 |
20060025821 | Gelfand | Feb 2006 | A1 |
20060030810 | Mandrusov | Feb 2006 | A1 |
20060074413 | Behzadian | Apr 2006 | A1 |
20060079838 | Walker | Apr 2006 | A1 |
20060079845 | Howard | Apr 2006 | A1 |
20060085054 | Zikorus | Apr 2006 | A1 |
20060089635 | Young | Apr 2006 | A1 |
20060106379 | O'Brien | May 2006 | A1 |
20060127703 | Takekuma | Jun 2006 | A1 |
20060142801 | Demarais | Jun 2006 | A1 |
20060149123 | Vidlund | Jul 2006 | A1 |
20060173490 | Lafontaine | Aug 2006 | A1 |
20060182684 | Beliveau | Aug 2006 | A1 |
20060184163 | Breen | Aug 2006 | A1 |
20060195146 | Tracey | Aug 2006 | A1 |
20060206150 | Demarais | Sep 2006 | A1 |
20060212032 | Daniel | Sep 2006 | A1 |
20060212076 | Demarais | Sep 2006 | A1 |
20060217702 | Young | Sep 2006 | A1 |
20060217704 | Cockburn | Sep 2006 | A1 |
20060224188 | Libbus | Oct 2006 | A1 |
20060224192 | Dimmer | Oct 2006 | A1 |
20060234752 | Mese | Oct 2006 | A1 |
20060235474 | Demarais | Oct 2006 | A1 |
20060241366 | Falwell | Oct 2006 | A1 |
20060247619 | Kaplan | Nov 2006 | A1 |
20060264807 | Westersten | Nov 2006 | A1 |
20060269531 | Beebe | Nov 2006 | A1 |
20060271111 | Demarais | Nov 2006 | A1 |
20060276710 | Krishnan | Dec 2006 | A1 |
20060278241 | Ruano | Dec 2006 | A1 |
20060283462 | Fields | Dec 2006 | A1 |
20060293713 | Rubinsky | Dec 2006 | A1 |
20060293725 | Rubinsky | Dec 2006 | A1 |
20060293730 | Rubinsky | Dec 2006 | A1 |
20060293731 | Rubinsky | Dec 2006 | A1 |
20060293734 | Scott | Dec 2006 | A1 |
20070016125 | Wong | Jan 2007 | A1 |
20070016183 | Lee | Jan 2007 | A1 |
20070016185 | Tullis | Jan 2007 | A1 |
20070021803 | Deem | Jan 2007 | A1 |
20070025919 | Deem | Feb 2007 | A1 |
20070043345 | Davalos | Feb 2007 | A1 |
20070055142 | Webler | Mar 2007 | A1 |
20070055225 | Dodd, III | Mar 2007 | A1 |
20070060989 | Deem | Mar 2007 | A1 |
20070066957 | Demarais | Mar 2007 | A1 |
20070066971 | Podhajsky | Mar 2007 | A1 |
20070078391 | Wortley | Apr 2007 | A1 |
20070078453 | Johnson | Apr 2007 | A1 |
20070083239 | Demarais | Apr 2007 | A1 |
20070088347 | Young | Apr 2007 | A1 |
20070093789 | Smith | Apr 2007 | A1 |
20070096048 | Clerc | May 2007 | A1 |
20070129711 | Altshuler | Jun 2007 | A1 |
20070129720 | Demarais | Jun 2007 | A1 |
20070129760 | Demarais | Jun 2007 | A1 |
20070137567 | Shimizu | Jun 2007 | A1 |
20070151848 | Novak | Jul 2007 | A1 |
20070153135 | Han | Jul 2007 | A1 |
20070156129 | Kovalcheck | Jul 2007 | A1 |
20070156135 | Rubinsky | Jul 2007 | A1 |
20070156136 | Godara | Jul 2007 | A1 |
20070173899 | Levin | Jul 2007 | A1 |
20070179380 | Grossman | Aug 2007 | A1 |
20070191589 | Hirota | Aug 2007 | A1 |
20070191889 | Lang | Aug 2007 | A1 |
20070197895 | Nycz | Aug 2007 | A1 |
20070203486 | Young | Aug 2007 | A1 |
20070203549 | Demarais | Aug 2007 | A1 |
20070230757 | Trachtenberg | Oct 2007 | A1 |
20070239099 | Goldfarb | Oct 2007 | A1 |
20070244521 | Bornzin | Oct 2007 | A1 |
20070249939 | Gerbi | Oct 2007 | A1 |
20070282407 | Demarais | Dec 2007 | A1 |
20070287950 | Kjeken | Dec 2007 | A1 |
20070295336 | Nelson | Dec 2007 | A1 |
20070295337 | Nelson | Dec 2007 | A1 |
20080015571 | Rubinsky | Jan 2008 | A1 |
20080015628 | Dubrul | Jan 2008 | A1 |
20080021371 | Rubinsky | Jan 2008 | A1 |
20080027314 | Miyazaki | Jan 2008 | A1 |
20080027343 | Fields | Jan 2008 | A1 |
20080033340 | Heller | Feb 2008 | A1 |
20080033417 | Nields | Feb 2008 | A1 |
20080045880 | Kjeken | Feb 2008 | A1 |
20080065062 | Leung | Mar 2008 | A1 |
20080071262 | Azure | Mar 2008 | A1 |
20080071264 | Azure | Mar 2008 | A1 |
20080071265 | Azure | Mar 2008 | A1 |
20080082145 | Skwarek | Apr 2008 | A1 |
20080086115 | Stoklund | Apr 2008 | A1 |
20080091135 | Draghia-Akli | Apr 2008 | A1 |
20080097139 | Clerc | Apr 2008 | A1 |
20080097422 | Edwards | Apr 2008 | A1 |
20080103529 | Schoenbach | May 2008 | A1 |
20080121375 | Richason | May 2008 | A1 |
20080125772 | Stone | May 2008 | A1 |
20080125775 | Morris | May 2008 | A1 |
20080132826 | Shadduck | Jun 2008 | A1 |
20080132884 | Rubinsky | Jun 2008 | A1 |
20080132885 | Rubinsky | Jun 2008 | A1 |
20080140064 | Vegesna | Jun 2008 | A1 |
20080146931 | Zhang | Jun 2008 | A1 |
20080146934 | Czygan | Jun 2008 | A1 |
20080147056 | Van Der Weide | Jun 2008 | A1 |
20080154259 | Gough | Jun 2008 | A1 |
20080167649 | Edwards | Jul 2008 | A1 |
20080171985 | Karakoca | Jul 2008 | A1 |
20080183256 | Keacher | Jul 2008 | A1 |
20080190434 | Tjong Joe Wai | Aug 2008 | A1 |
20080200911 | Long | Aug 2008 | A1 |
20080200912 | Long | Aug 2008 | A1 |
20080208052 | Lepivert | Aug 2008 | A1 |
20080210243 | Clayton | Sep 2008 | A1 |
20080213331 | Gelfand | Sep 2008 | A1 |
20080214986 | Ivorra | Sep 2008 | A1 |
20080224188 | Han | Sep 2008 | A1 |
20080234708 | Houser | Sep 2008 | A1 |
20080236593 | Nelson | Oct 2008 | A1 |
20080249503 | Fields | Oct 2008 | A1 |
20080255553 | Young | Oct 2008 | A1 |
20080262489 | Steinke | Oct 2008 | A1 |
20080269586 | Rubinsky | Oct 2008 | A1 |
20080269838 | Brighton | Oct 2008 | A1 |
20080275465 | Paul | Nov 2008 | A1 |
20080279995 | Schultheiss | Nov 2008 | A1 |
20080281319 | Paul | Nov 2008 | A1 |
20080283065 | Chang | Nov 2008 | A1 |
20080288038 | Paul | Nov 2008 | A1 |
20080294155 | Cronin | Nov 2008 | A1 |
20080294358 | Richardson | Nov 2008 | A1 |
20080306427 | Bailey | Dec 2008 | A1 |
20080312599 | Rosenberg | Dec 2008 | A1 |
20080319511 | Pless | Dec 2008 | A1 |
20090018206 | Barkan | Jan 2009 | A1 |
20090018565 | To | Jan 2009 | A1 |
20090018566 | Escudero | Jan 2009 | A1 |
20090018567 | Escudero | Jan 2009 | A1 |
20090024075 | Schroeppel | Jan 2009 | A1 |
20090024085 | To | Jan 2009 | A1 |
20090029407 | Gazit | Jan 2009 | A1 |
20090030336 | Woo | Jan 2009 | A1 |
20090036773 | Lau | Feb 2009 | A1 |
20090038752 | Weng | Feb 2009 | A1 |
20090062788 | Long | Mar 2009 | A1 |
20090062792 | Vakharia | Mar 2009 | A1 |
20090062795 | Vakharia | Mar 2009 | A1 |
20090076496 | Azure | Mar 2009 | A1 |
20090076499 | Azure | Mar 2009 | A1 |
20090076500 | Azure | Mar 2009 | A1 |
20090076502 | Azure | Mar 2009 | A1 |
20090081272 | Clarke | Mar 2009 | A1 |
20090088636 | Lau | Apr 2009 | A1 |
20090099544 | Munrow | Apr 2009 | A1 |
20090105703 | Shadduck | Apr 2009 | A1 |
20090114226 | Deem | May 2009 | A1 |
20090118725 | Auth | May 2009 | A1 |
20090118729 | Auth | May 2009 | A1 |
20090125009 | Zikorus | May 2009 | A1 |
20090138014 | Bonutti | May 2009 | A1 |
20090143705 | Danek | Jun 2009 | A1 |
20090157166 | Singhal | Jun 2009 | A1 |
20090163904 | Miller | Jun 2009 | A1 |
20090171280 | Samuel | Jul 2009 | A1 |
20090177111 | Miller | Jul 2009 | A1 |
20090186850 | Kiribayashi | Jul 2009 | A1 |
20090192508 | Laufer | Jul 2009 | A1 |
20090198227 | Prakash | Aug 2009 | A1 |
20090204005 | Keast | Aug 2009 | A1 |
20090204112 | Kleyman | Aug 2009 | A1 |
20090209955 | Forster | Aug 2009 | A1 |
20090216543 | Pang | Aug 2009 | A1 |
20090221939 | Demarais | Sep 2009 | A1 |
20090228001 | Pacey | Sep 2009 | A1 |
20090240247 | Rioux | Sep 2009 | A1 |
20090247933 | Maor | Oct 2009 | A1 |
20090248012 | Maor | Oct 2009 | A1 |
20090269317 | Davalos | Oct 2009 | A1 |
20090270756 | Gamache | Oct 2009 | A1 |
20090275827 | Aiken | Nov 2009 | A1 |
20090281477 | Mikus | Nov 2009 | A1 |
20090281540 | Blomgren | Nov 2009 | A1 |
20090287081 | Grossman | Nov 2009 | A1 |
20090292342 | Rubinsky | Nov 2009 | A1 |
20090301480 | Elsakka | Dec 2009 | A1 |
20090306544 | Ng | Dec 2009 | A1 |
20090306545 | Elsakka | Dec 2009 | A1 |
20090318849 | Hobbs | Dec 2009 | A1 |
20090318905 | Bhargav | Dec 2009 | A1 |
20090326366 | Krieg | Dec 2009 | A1 |
20090326436 | Rubinsky | Dec 2009 | A1 |
20090326561 | Carroll, II | Dec 2009 | A1 |
20090326570 | Brown | Dec 2009 | A1 |
20100006441 | Renaud | Jan 2010 | A1 |
20100016783 | Bourke, Jr. | Jan 2010 | A1 |
20100023004 | Francischelli | Jan 2010 | A1 |
20100030211 | Davalos | Feb 2010 | A1 |
20100036291 | Darlington | Feb 2010 | A1 |
20100049190 | Long | Feb 2010 | A1 |
20100056926 | Deckman | Mar 2010 | A1 |
20100057074 | Roman | Mar 2010 | A1 |
20100057076 | Behnke | Mar 2010 | A1 |
20100069921 | Miller | Mar 2010 | A1 |
20100079215 | Brannan | Apr 2010 | A1 |
20100082022 | Haley | Apr 2010 | A1 |
20100082023 | Brannan | Apr 2010 | A1 |
20100082024 | Brannan | Apr 2010 | A1 |
20100082025 | Brannan | Apr 2010 | A1 |
20100082083 | Brannan | Apr 2010 | A1 |
20100082084 | Brannan | Apr 2010 | A1 |
20100087813 | Long | Apr 2010 | A1 |
20100090696 | Deimling | Apr 2010 | A1 |
20100100093 | Azure | Apr 2010 | A1 |
20100106025 | Sarfaty | Apr 2010 | A1 |
20100106047 | Sarfaty | Apr 2010 | A1 |
20100121173 | Sarfaty | May 2010 | A1 |
20100130975 | Long | May 2010 | A1 |
20100147701 | Field | Jun 2010 | A1 |
20100152725 | Pearson | Jun 2010 | A1 |
20100160850 | Ivorra | Jun 2010 | A1 |
20100168735 | Deno | Jul 2010 | A1 |
20100174282 | Demarais | Jul 2010 | A1 |
20100179436 | Sarfaty | Jul 2010 | A1 |
20100179530 | Long | Jul 2010 | A1 |
20100191112 | Demarais | Jul 2010 | A1 |
20100191235 | Moshe | Jul 2010 | A1 |
20100196984 | Rubinsky | Aug 2010 | A1 |
20100204560 | Salahieh | Aug 2010 | A1 |
20100204638 | Hobbs | Aug 2010 | A1 |
20100211061 | Leyh | Aug 2010 | A1 |
20100222377 | Crooks | Sep 2010 | A1 |
20100222677 | Placek | Sep 2010 | A1 |
20100228234 | Hyde | Sep 2010 | A1 |
20100228247 | Paul | Sep 2010 | A1 |
20100241117 | Paul | Sep 2010 | A1 |
20100249771 | Pearson | Sep 2010 | A1 |
20100255795 | Rubinsky | Oct 2010 | A1 |
20100256624 | Brannan | Oct 2010 | A1 |
20100256628 | Pearson | Oct 2010 | A1 |
20100256630 | Hamilton, Jr. | Oct 2010 | A1 |
20100261994 | Davalos | Oct 2010 | A1 |
20100262067 | Chornenky | Oct 2010 | A1 |
20100268223 | Coe | Oct 2010 | A1 |
20100268225 | Coe | Oct 2010 | A1 |
20100286690 | Paul | Nov 2010 | A1 |
20100292686 | Rick | Nov 2010 | A1 |
20100298822 | Behnke | Nov 2010 | A1 |
20100298823 | Cao | Nov 2010 | A1 |
20100298825 | Slizynski | Nov 2010 | A1 |
20100331758 | Davalos | Dec 2010 | A1 |
20100331911 | Kovalcheck | Dec 2010 | A1 |
20110009860 | Chornenky | Jan 2011 | A1 |
20110015630 | Azure | Jan 2011 | A1 |
20110017207 | Hendricksen | Jan 2011 | A1 |
20110021970 | Vo-Dinh | Jan 2011 | A1 |
20110034209 | Rubinsky | Feb 2011 | A1 |
20110054458 | Behnke | Mar 2011 | A1 |
20110064371 | Leatherman | Mar 2011 | A1 |
20110064671 | Bynoe | Mar 2011 | A1 |
20110082362 | Schmidt | Apr 2011 | A1 |
20110082414 | Wallace | Apr 2011 | A1 |
20110092973 | Nuccitelli | Apr 2011 | A1 |
20110098695 | Brannan | Apr 2011 | A1 |
20110105823 | Single, Jr. | May 2011 | A1 |
20110106221 | Neal, II | May 2011 | A1 |
20110112434 | Ghabrial | May 2011 | A1 |
20110112531 | Landis | May 2011 | A1 |
20110118721 | Brannan | May 2011 | A1 |
20110118727 | Fish | May 2011 | A1 |
20110118729 | Heeren | May 2011 | A1 |
20110118732 | Rubinsky | May 2011 | A1 |
20110118734 | Auld | May 2011 | A1 |
20110130834 | Wilson | Jun 2011 | A1 |
20110135626 | Kovalcheck | Jun 2011 | A1 |
20110144524 | Fish | Jun 2011 | A1 |
20110144562 | Heeren | Jun 2011 | A1 |
20110144638 | Heeren | Jun 2011 | A1 |
20110144641 | Dimalanta, Jr. | Jun 2011 | A1 |
20110144657 | Fish | Jun 2011 | A1 |
20110152678 | Aljuri | Jun 2011 | A1 |
20110152906 | Escudero | Jun 2011 | A1 |
20110152907 | Escudero | Jun 2011 | A1 |
20110160514 | Long | Jun 2011 | A1 |
20110166499 | Demarais | Jul 2011 | A1 |
20110172659 | Brannan | Jul 2011 | A1 |
20110176037 | Benkley, III | Jul 2011 | A1 |
20110178570 | Demarais | Jul 2011 | A1 |
20110202052 | Gelbart | Aug 2011 | A1 |
20110202053 | Moss | Aug 2011 | A1 |
20110207758 | Sobotka | Aug 2011 | A1 |
20110208096 | Demarais | Aug 2011 | A1 |
20110208180 | Brannan | Aug 2011 | A1 |
20110217730 | Gazit | Sep 2011 | A1 |
20110230874 | Epstein | Sep 2011 | A1 |
20110245756 | Arora | Oct 2011 | A1 |
20110251607 | Kruecker | Oct 2011 | A1 |
20110282354 | Schulte | Nov 2011 | A1 |
20110288545 | Beebe | Nov 2011 | A1 |
20110301587 | Deem | Dec 2011 | A1 |
20110306971 | Long | Dec 2011 | A1 |
20120034131 | Rubinsky | Feb 2012 | A1 |
20120046658 | Kreindel | Feb 2012 | A1 |
20120059255 | Paul | Mar 2012 | A1 |
20120071870 | Salahieh | Mar 2012 | A1 |
20120071872 | Rubinsky | Mar 2012 | A1 |
20120071874 | Davalos | Mar 2012 | A1 |
20120085649 | Sano | Apr 2012 | A1 |
20120089009 | Omary | Apr 2012 | A1 |
20120090643 | Bertsch | Apr 2012 | A1 |
20120090646 | Tanaka | Apr 2012 | A1 |
20120095459 | Callas | Apr 2012 | A1 |
20120101538 | Ballakur | Apr 2012 | A1 |
20120109122 | Arena | May 2012 | A1 |
20120130289 | Demarais | May 2012 | A1 |
20120150172 | Ortiz | Jun 2012 | A1 |
20120165813 | Lee | Jun 2012 | A1 |
20120179091 | Ivorra | Jul 2012 | A1 |
20120220999 | Long | Aug 2012 | A1 |
20120226218 | Phillips | Sep 2012 | A1 |
20120226271 | Callas | Sep 2012 | A1 |
20120265183 | Tulleken et al. | Oct 2012 | A1 |
20120265186 | Burger | Oct 2012 | A1 |
20120277741 | Davalos | Nov 2012 | A1 |
20120303012 | Leyh | Nov 2012 | A1 |
20120303020 | Chornenky | Nov 2012 | A1 |
20120310236 | Placek | Dec 2012 | A1 |
20120310237 | Swanson | Dec 2012 | A1 |
20130023871 | Collins | Jan 2013 | A1 |
20130030239 | Weyh | Jan 2013 | A1 |
20130030430 | Stewart | Jan 2013 | A1 |
20130033977 | Lin | Feb 2013 | A1 |
20130035921 | Rodriguez-Ponce | Feb 2013 | A1 |
20130041436 | Ruse | Feb 2013 | A1 |
20130072858 | Watson | Mar 2013 | A1 |
20130090346 | Johns | Apr 2013 | A1 |
20130090646 | Moss | Apr 2013 | A1 |
20130108667 | Soikum | May 2013 | A1 |
20130110103 | Assmus | May 2013 | A1 |
20130110106 | Richardson | May 2013 | A1 |
20130184702 | Neal, II | Jul 2013 | A1 |
20130196441 | Rubinsky | Aug 2013 | A1 |
20130197425 | Golberg | Aug 2013 | A1 |
20130202766 | Rubinsky | Aug 2013 | A1 |
20130218157 | Callas | Aug 2013 | A1 |
20130230895 | Koblizek | Sep 2013 | A1 |
20130238062 | Ron Edoute | Sep 2013 | A1 |
20130253415 | Sano | Sep 2013 | A1 |
20130261389 | Long | Oct 2013 | A1 |
20130281968 | Davalos | Oct 2013 | A1 |
20130296679 | Condie | Nov 2013 | A1 |
20130338761 | Plowiecki | Dec 2013 | A1 |
20130345697 | Garcia | Dec 2013 | A1 |
20130345779 | Maor | Dec 2013 | A1 |
20140005664 | Govari | Jan 2014 | A1 |
20140017218 | Scott | Jan 2014 | A1 |
20140039489 | Davalos | Feb 2014 | A1 |
20140046322 | Callas | Feb 2014 | A1 |
20140052118 | Laske | Feb 2014 | A1 |
20140066913 | Sherman | Mar 2014 | A1 |
20140081255 | Johnson | Mar 2014 | A1 |
20140088578 | Rubinsky | Mar 2014 | A1 |
20140094792 | Sharonov | Apr 2014 | A1 |
20140094793 | Sharonov | Apr 2014 | A1 |
20140107643 | Chornenky | Apr 2014 | A1 |
20140111224 | Agate | Apr 2014 | A1 |
20140121663 | Pearson | May 2014 | A1 |
20140121728 | Dhillon | May 2014 | A1 |
20140163551 | Maor | Jun 2014 | A1 |
20140207133 | Model | Jul 2014 | A1 |
20140276748 | Ku | Sep 2014 | A1 |
20140296844 | Kevin | Oct 2014 | A1 |
20140309579 | Rubinsky | Oct 2014 | A1 |
20140378964 | Pearson | Dec 2014 | A1 |
20150025526 | Hua | Jan 2015 | A1 |
20150032105 | Azure | Jan 2015 | A1 |
20150066013 | Salahieh | Mar 2015 | A1 |
20150066020 | Epstein | Mar 2015 | A1 |
20150088120 | Garcia | Mar 2015 | A1 |
20150088220 | Callas | Mar 2015 | A1 |
20150112333 | Chorenky | Apr 2015 | A1 |
20150126922 | Willis | May 2015 | A1 |
20150134584 | Nakagawa | May 2015 | A1 |
20150141984 | Loomas | May 2015 | A1 |
20150152504 | Lin | Jun 2015 | A1 |
20150164584 | Davalos | Jun 2015 | A1 |
20150173824 | Davalos | Jun 2015 | A1 |
20150196351 | Stone | Jul 2015 | A1 |
20150201996 | Rubinsky | Jul 2015 | A1 |
20150265349 | Moss | Sep 2015 | A1 |
20150289923 | Davalos | Oct 2015 | A1 |
20150320478 | Cosman, Jr. | Nov 2015 | A1 |
20150320481 | Cosman, Jr. | Nov 2015 | A1 |
20150320488 | Moshe | Nov 2015 | A1 |
20150320999 | Nuccitelli | Nov 2015 | A1 |
20150327944 | Neal, II | Nov 2015 | A1 |
20160022957 | Hobbs | Jan 2016 | A1 |
20160066977 | Neal, II | Mar 2016 | A1 |
20160074114 | Pearson | Mar 2016 | A1 |
20160113708 | Moss | Apr 2016 | A1 |
20160143398 | Kim | May 2016 | A1 |
20160143698 | Garcia | May 2016 | A1 |
20160235470 | Callas | Aug 2016 | A1 |
20160287313 | Rubinsky | Oct 2016 | A1 |
20160287314 | Arena | Oct 2016 | A1 |
20160337310 | Faccin | Nov 2016 | A1 |
20160338758 | Davalos | Nov 2016 | A9 |
20160338761 | Chornenky | Nov 2016 | A1 |
20160354142 | Pearson | Dec 2016 | A1 |
20160367310 | Onik | Dec 2016 | A1 |
20170035501 | Chornenky | Feb 2017 | A1 |
20170065339 | Mickelsen | Mar 2017 | A1 |
20170137512 | Van Hoorick | May 2017 | A1 |
20170189579 | Davalos | Jul 2017 | A1 |
20170209620 | Davalos | Jul 2017 | A1 |
20170266438 | Sano | Sep 2017 | A1 |
20170319851 | Athos | Nov 2017 | A1 |
20170348525 | Sano | Dec 2017 | A1 |
20170360323 | Li | Dec 2017 | A1 |
20170360326 | Davalos | Dec 2017 | A1 |
20180071014 | Neal | Mar 2018 | A1 |
20180125565 | Sano | May 2018 | A1 |
20180161086 | Davalos | Jun 2018 | A1 |
20180198218 | Regan | Jul 2018 | A1 |
20190023804 | Onik | Jan 2019 | A1 |
20190029749 | Garcia | Jan 2019 | A1 |
20190046255 | Davalos | Feb 2019 | A1 |
20190069945 | Davalos | Mar 2019 | A1 |
20190076528 | Soden | Mar 2019 | A1 |
20190083169 | Single | Mar 2019 | A1 |
20190133671 | Davalos | May 2019 | A1 |
20190175248 | Neal, II | Jun 2019 | A1 |
20190175260 | Davalos | Jun 2019 | A1 |
20190223938 | Arena | Jul 2019 | A1 |
20190232048 | Latouche | Aug 2019 | A1 |
20190233809 | Neal, II | Aug 2019 | A1 |
20190256839 | Neal, II | Aug 2019 | A1 |
20190282294 | Davalos | Sep 2019 | A1 |
20190328445 | Sano | Oct 2019 | A1 |
20190351224 | Sano | Nov 2019 | A1 |
20190376055 | Davalos | Dec 2019 | A1 |
20200046432 | Garcia | Feb 2020 | A1 |
20200046967 | Ivey | Feb 2020 | A1 |
20200093541 | Neal et al. | Mar 2020 | A9 |
20200197073 | Sano | Jun 2020 | A1 |
20200260987 | Davalos | Aug 2020 | A1 |
20200289188 | Forsyth | Sep 2020 | A1 |
20200323576 | Neal | Oct 2020 | A1 |
20200405373 | O'Brien | Dec 2020 | A1 |
20210022795 | Davalos | Jan 2021 | A1 |
20210023362 | Lorenzo | Jan 2021 | A1 |
20210052882 | Wasson | Feb 2021 | A1 |
20210113265 | D'Agostino | Apr 2021 | A1 |
20210137410 | O'Brien | May 2021 | A1 |
20210186600 | Davalos | Jun 2021 | A1 |
20210361341 | Neal, II | Nov 2021 | A1 |
20210393312 | Davalos | Dec 2021 | A1 |
20220151688 | Garcia | May 2022 | A1 |
20220161027 | Aycock | May 2022 | A1 |
20220290183 | Davalos | Sep 2022 | A1 |
20220362549 | Sano | Nov 2022 | A1 |
20230157759 | Garcia | May 2023 | A1 |
20230212551 | Neal, II | Jul 2023 | A1 |
20230248414 | Sano | Aug 2023 | A1 |
20230355293 | Davalos | Nov 2023 | A1 |
20230355968 | Davalos | Nov 2023 | A1 |
Number | Date | Country |
---|---|---|
7656800 | Apr 2001 | AU |
2002315095 | Dec 2002 | AU |
2003227960 | Dec 2003 | AU |
2005271471 | Feb 2006 | AU |
2006321570 | Jun 2007 | AU |
2006321574 | Jun 2007 | AU |
2006321918 | Jun 2007 | AU |
2009243079 | Jan 2011 | AU |
2012255070 | Jan 2014 | AU |
2015259303 | Nov 2016 | AU |
2297846 | Feb 1999 | CA |
2378110 | Feb 2001 | CA |
2445392 | Nov 2002 | CA |
2458676 | Mar 2003 | CA |
2487284 | Dec 2003 | CA |
2575792 | Feb 2006 | CA |
2631940 | Jun 2007 | CA |
2631946 | Jun 2007 | CA |
2632604 | Jun 2007 | CA |
2722296 | Nov 2009 | CA |
2751462 | Nov 2010 | CA |
1525839 | Sep 2004 | CN |
101534736 | Sep 2009 | CN |
102238921 | Nov 2011 | CN |
102421386 | Apr 2012 | CN |
106715682 | May 2017 | CN |
112807074 | May 2021 | CN |
833111 | Mar 1952 | DE |
60038026 | Feb 2009 | DE |
60038026 | Feb 2009 | DE |
0218275 | Apr 1987 | EP |
0339501 | Nov 1989 | EP |
0528891 | Mar 1993 | EP |
0533511 | Mar 1993 | EP |
0908156 | Apr 1999 | EP |
0998235 | May 2000 | EP |
1011495 | Jun 2000 | EP |
0528891 | Jul 2000 | EP |
1061983 | Dec 2000 | EP |
1196550 | Apr 2002 | EP |
1207797 | May 2002 | EP |
1344497 | Sep 2003 | EP |
1406685 | Apr 2004 | EP |
1424970 | Jun 2004 | EP |
1439792 | Jul 2004 | EP |
1442765 | Aug 2004 | EP |
1462065 | Sep 2004 | EP |
1061983 | Nov 2004 | EP |
1493397 | Jan 2005 | EP |
1506039 | Feb 2005 | EP |
0935482 | May 2005 | EP |
1011495 | Nov 2005 | EP |
1791485 | Jun 2007 | EP |
1796568 | Jun 2007 | EP |
1207797 | Feb 2008 | EP |
1406685 | Jun 2008 | EP |
1962708 | Sep 2008 | EP |
1962710 | Sep 2008 | EP |
1962945 | Sep 2008 | EP |
1424970 | Dec 2008 | EP |
2280741 | Feb 2011 | EP |
2373241 | Oct 2011 | EP |
2381829 | Nov 2011 | EP |
2413833 | Feb 2012 | EP |
2429435 | Mar 2012 | EP |
2488251 | Aug 2012 | EP |
2593179 | May 2013 | EP |
2627274 | Aug 2013 | EP |
2642937 | Oct 2013 | EP |
2651505 | Oct 2013 | EP |
3143124 | Mar 2017 | EP |
3852868 | Jul 2021 | EP |
2300272 | Jun 2008 | ES |
2315493 | Apr 2009 | ES |
H10243947 | Sep 1998 | JP |
2001510702 | Aug 2001 | JP |
2002360712 | Dec 2002 | JP |
2003505072 | Feb 2003 | JP |
2003506064 | Feb 2003 | JP |
2004203224 | Jul 2004 | JP |
2004525726 | Aug 2004 | JP |
2004303590 | Oct 2004 | JP |
2005501596 | Jan 2005 | JP |
2005526579 | Sep 2005 | JP |
2007516792 | Jun 2007 | JP |
2008508946 | Mar 2008 | JP |
4252316 | Apr 2009 | JP |
4252316 | Apr 2009 | JP |
2009518130 | May 2009 | JP |
2009518150 | May 2009 | JP |
2009518151 | May 2009 | JP |
2009532077 | Sep 2009 | JP |
2009532077 | Sep 2009 | JP |
2010503496 | Feb 2010 | JP |
2010503496 | Feb 2010 | JP |
2010511467 | Apr 2010 | JP |
2011137025 | Jul 2011 | JP |
2012510332 | May 2012 | JP |
2012515018 | Jul 2012 | JP |
2012515018 | Jul 2012 | JP |
2012521863 | Sep 2012 | JP |
2014501574 | Jan 2014 | JP |
2017518805 | Jul 2017 | JP |
6594901 | Oct 2019 | JP |
2019193668 | Nov 2019 | JP |
7051188 | Apr 2022 | JP |
101034682 | Apr 2004 | KR |
9104014 | Apr 1991 | WO |
9614238 | May 1996 | WO |
9634571 | Nov 1996 | WO |
9810745 | Mar 1998 | WO |
9814238 | Apr 1998 | WO |
9901076 | Jan 1999 | WO |
9904710 | Feb 1999 | WO |
0020554 | Apr 2000 | WO |
0110319 | Feb 2001 | WO |
2001048153 | Jul 2001 | WO |
0170114 | Sep 2001 | WO |
0200554 | Jan 2002 | WO |
02078527 | Oct 2002 | WO |
02089686 | Nov 2002 | WO |
02100459 | Dec 2002 | WO |
2003020144 | Mar 2003 | WO |
2003047684 | Jun 2003 | WO |
03099382 | Dec 2003 | WO |
2004008153 | Jan 2004 | WO |
2004080347 | Sep 2004 | WO |
2005065284 | Jul 2005 | WO |
2006017666 | Feb 2006 | WO |
2006031541 | Mar 2006 | WO |
2006130194 | Dec 2006 | WO |
2007067628 | Jun 2007 | WO |
2007067937 | Jun 2007 | WO |
2007067938 | Jun 2007 | WO |
2007067939 | Jun 2007 | WO |
2007067940 | Jun 2007 | WO |
2007067941 | Jun 2007 | WO |
2007067943 | Jun 2007 | WO |
2007070361 | Jun 2007 | WO |
2007100727 | Sep 2007 | WO |
2007123690 | Nov 2007 | WO |
2007137303 | Nov 2007 | WO |
2008034103 | Mar 2008 | WO |
2008063195 | May 2008 | WO |
2008101086 | Aug 2008 | WO |
2008101091 | Aug 2008 | WO |
2009036468 | Mar 2009 | WO |
2009046176 | Apr 2009 | WO |
2009134876 | Nov 2009 | WO |
2009135070 | Nov 2009 | WO |
2009137800 | Nov 2009 | WO |
2010015592 | Feb 2010 | WO |
2010064154 | Jun 2010 | WO |
2010080974 | Jul 2010 | WO |
2010085765 | Jul 2010 | WO |
2010117806 | Oct 2010 | WO |
2010118387 | Oct 2010 | WO |
2010128373 | Nov 2010 | WO |
2010132472 | Nov 2010 | WO |
2010151277 | Dec 2010 | WO |
2011028937 | Mar 2011 | WO |
2011047387 | Apr 2011 | WO |
2011047387 | Apr 2011 | WO |
2011062653 | May 2011 | WO |
2011072221 | Jun 2011 | WO |
2011135294 | Nov 2011 | WO |
2012006533 | Jan 2012 | WO |
2012051433 | Apr 2012 | WO |
2012054560 | Apr 2012 | WO |
2012054573 | Apr 2012 | WO |
2012063266 | May 2012 | WO |
2012071526 | May 2012 | WO |
2012071526 | May 2012 | WO |
2012088149 | Jun 2012 | WO |
2012088149 | Jun 2012 | WO |
2012140376 | Oct 2012 | WO |
2013052138 | Apr 2013 | WO |
2013176881 | Nov 2013 | WO |
2014039320 | Mar 2014 | WO |
2015175570 | Nov 2015 | WO |
2015192027 | Dec 2015 | WO |
2016100325 | Jun 2016 | WO |
2016164930 | Oct 2016 | WO |
2017024123 | Feb 2017 | WO |
2017117418 | Jul 2017 | WO |
2020061192 | Mar 2020 | WO |
2022066768 | Mar 2022 | WO |
2023172773 | Sep 2023 | WO |
Entry |
---|
Sel, D. et al. Sequential finite element model of tissue electropermeabilization. IEEE Transactions on Biomedical Engineering 52, 816-827, doi:10.1109/tbme.2005.845212 (2005). |
Sel, D., Lebar, A. M. & Miklavcic, D. Feasibility of employing model-based optimization of pulse amplitude and electrode distance for effective tumor electropermeabilization. IEEE Trans Biomed Eng 54, 773-781 (2007). |
Sersa, et al, Tumor blood flow modifying effect of electrochemotherapy with Bleomycin, Anticancer Research, 1999, 19, pp. 4017-4022. |
Shafiee, et al, A preliminary study to delineate irreversible electroporation from thermal damage using the Arrhenius equation, Journal of Biomedical Engineering, Jul. 2009, vol. 131, 074509, pp. 1-5. |
Shao, Qi et al. Engineering T cell response to cancer antigens by choice of focal therapeutic conditions, International Journal of Hyperthermia, 2019, DOI: 10.1080/02656736.2018.1539253. |
Sharma, A., et al., “Review on Thermal Energy Storage with Phase Change Materials and Applications”, Renewable Sustainable Energy Rev. 13(2), 318-345 (2009). |
Soden, et al, Successful application of targeted electrochemotherapy using novel flexible electrodes and low dose bleomycin to solid tumors, Cancer Letters, 2006, 232 pp. 300-310. |
Son, et al, Basic features of a cell electroporation model: illustrative behavior for tw overy different pulses, J Membrane Biol, Jul. 22, 2014, 247, pp. 1209-1228. |
Song, Z.Q., et al., Mechanisms for steep pulse irreversible electroporation technology to kill human large cell lung cancer cells L9981. International Journal of Clinical and Experimental Medicine, 2014. 7(8): p. 2386-2394. |
Szot et al., “3D in vitro bioengineered tumors based on collagen I hydrogels.” Biomaterials vol. 32, pp. 7905-7912 (2011). |
Talele, S. and P. Gaynor, “Non-linear time domain model of electropermeabilization: Effect of extracellular conductivity and applied electric field parameters”, Journal of Electrostatics,66(5-6): p. 328-334 (2008). |
Talele, S. and P. Gaynor, “Non-linear time domain model of electropermeabilization: Response of a single cell to an arbitrary applied electric field”, Journal of Electrostatics, 65(12): p. 775-784 (2007). |
Talele, S., et al., “Modelling single cell electroporation with bipolar pulse parameters and dynamic pore radii”. Journal of Electrostatics, 68(3): p. 261-274 (2010). |
Teissie, J. and T.Y. Tsong, “Electric-Field Induced Transient Pores in Phospholipid-Bilayer Vesicles”. Biochemistry, 20(6): p. 1548-1554(1981). |
Tekle, et al., “Electroporation by using bipolar oscillating electric field: An improved method for DNA transfection of NIF 3T3 cells,” Proc. Natl. Acad. Sci., Biochemistry, vol. 88, pp. 4230-4234, May 1991. |
Thomson, Human experience with irreversible electroporation, Irreversible Electroporation, Biomed, 2010, pp. 249-354. |
Thomson, K. R., et al., “Investigation of the Safety of Irreversible Electroporation in Humans” J. Vascular Int. Radiol. 22(5), 611-621 (2011). |
Tibbitt et al., “Hydrogels as Extracellular Matrix Mimics for 3D Cell Culture”, Jul. 2009, Biotechnol Bioeng, 103(4),655-663. |
Tijink, et al, How we do it: Chemo-electroporation in the head and neck for otherwise untreatable patients, Correspondence, Clinical Otolaryngology, 2006, 31, pp. 447-451. |
Tracy, et al, Irreversible electroporation (IRE): A novel method for renal tissue ablation, BJU International, 107, pp. 1982-1987. |
Trimmer, et al, Minimally invasive percutaneous treatment of small renal tumors with irreversible electroporation: a single-center experience, J Vasc Intery Radiol, 2015, 26: pp. 1465-1471. |
Troszak, et al., Self-powered electroporation using a singularity-induced nano-electroporation configuration, Biochemical and Biophysical Research Communications, Sep. 28, 2011, 414, pp. 419-424. |
Tsivian, Polascik, Recent advances in focal therapy of prostate and kidney cancer, Medicine Reports, Jan. 18, 2010, 2, 1, pp. 1-3. |
Valdez, C. M. et al., The interphase interval within a bipolar nanosecond electric pulse modulates bipolar cancellation, Bioelectromagnetics, vol. 39, No. 6,441-450, 2018, 28 pages. |
Van Den Bos, W. et al., “MRI and contrast-enhanced ultrasound imaging for evaluation offocal irreversible electroporation treatment: results from a phase i-ii study in patients undergoing ire followed by radical prostatectomy,” European radiology, vol. 26, No. 7, pp. 2252-2260, 2016. |
Verbridge et al., “Oxygen-Controlled Three-Dimensional Cultures to Analyze Tumor Angiogenesis.” Tissue Engineering, Part A vol. 16, pp. 2133-2141 (2010). |
Verma, A. et al., “Primer on Pulsed Electrical Field Ablation: Understanding the Benefits and Limitations,” Circ. Arrhythmia Electrophysiol., No. September, pp. 1-16,2021,16 pages. |
Vernier, P.T., et al., “Nanoelectropulse-driven membrane perturbation and small molecule permeabilization”, Bmc Cell Biology, 7 (2006). |
Vi{hacek over (z)}intin, A. et al., “Effect of interphase and interpulse delay in high-frequency irreversible electroporation pulses on cell survival, membrane permeabilization and electrode material release,” Bioelectrochemistry, vol. 134, Aug. 2020,14 Pages. |
Voyer, D., A. Silve, L. M. Mir, R. Scorretti, and C. Poignard, “Dynamical modeling of tissue electroporation,” Bioelectrochemistry, vol. 119, pp. 98-110, 2018. |
Wandel, A. et al. “Optimizing Irreversible Electroporation Ablation with a Bipolar Electrode,” Journal of Vascular and Interventional Radiology, vol. 27, Issue 9, 1441-1450.e2, 2016. |
Wasson, Elisa M. et al. The Feasibility of Enhancing Susceptibility of Glioblastoma Cells to IRE Using a Calcium Adjuvant. Annals of Biomedical Engineering, vol. 45, No. 11, Nov. 2017 pp. 2535-2547. |
Weaver et al., “A brief overview of electroporation pulse strength-duration space: A region where additional ntracellular effects are expected.” Bioelectrochemistry vol. 87, pp. 236-243 (2012). |
Weaver, J. C., Electroporation of biological membranes from multicellular to nano scales, IEEE Tms. Dielectr. Electr. Insul. 10, 754-768 (2003). |
Weaver, J.C., “Electroporation of cells and tissues”, IEEE Transactions on Plasma Science, 28(1): p. 24-33 (2000). |
Weisstein: Cassini Ovals. From MathWorld—A. Wolfram Web Resource; Apr. 30, 2010; http://mathworld.wolfram.com/ (updated May 18, 2011) 2 pages. |
Wimmer, Thomas, et al., “Planning Irreversible Electroporation (IRE) in the Porcine Kidney: Are Numerical Simulations Reliable for Predicting Empiric Ablation Outcomes?”, Cardiovasc Intervent Radiol. Feb. 2015 ; 38(1): 182-190. doi:10.1007/s00270-014-0905-2. |
Wittkampf, et al, Myocardial lesion depth with circular electroporation ablation, Circ Arrhythm Electrophysiol, 2012, 5, pp. 581-586. |
Wood et al., Technologies for Guidance of Radiofrequency Ablation in the Multimodality Interventional Suite of the Future, Jan. 2007, National Institutes of Health, pp. 1-26. |
Wright, On a relationship between the arrhenius parameters from thermal damage studies, Technical Brief, Journalof Biomechanical Engineering, Transactions of the ASME, Apr. 2003, vol. 125, pp. 300-304. |
Yang et al., “Dielectric properties of human leukocyte subpopulations determined by selectrorotation as a cell separation criterion.” Biophysical Journal, vol. 76, pp. 3307-3314 (1999). |
Yao et al., “Study of transmembrane potentials of inner and outer membranes induced by pulsed-electric-field model and simulation.” IEEE Trans Plasma Sci, 2007. 35(5): p. 1541-1549. |
Yarmush, M. L. et al., “Electroporation-Based Technologies for Medicine: Principles, Applications, and Challenges,” Annu. Rev. Biomed. Eng., vol. 16, No. 1,295-320, 2014, 29 pages. |
Ybarra, Gary A, et al. “Breast Imaging using Electrical Impedance Tomography.” in Suri, J.S., R.M. Rangayyan, and S. Laxminarayan, Emerging Technologies in Breast Imaging and Mammography2008: American Scientific Publishers. |
Zhang, et al, MR imaging to assess immediate response to irreversible electroporation for targeted ablation of liver tissues: Preclinical feasibility studies in a rodent model, Radiology, Aug. 2010, vol. 256, No. 2, pp. 424-432. |
Zhao, J. et al. “Irreversible electroporation reverses resistance to immune checkpoint blockade in pancreatic cancer”, Nature Communications (2019) 10:899,14 pages. |
Zhao, Y., S. Bhonsle, S. Dong, Y. Lv, H. Liu, A. Safaai-Jazi, R. V. Davalos, and C. Yao, “Characterization of conductivity changes during high-frequency irreversible electroporation for treatment planning,” IEEE Transactions on Biomedical Engineering, vol. 65, No. 8, pp. 1810-1819,2017. |
Zhou, et al, Electroporation-mediated transfer of plasmids to the lung results in reduced TLR9 signaling and Inflammation, Gene Therapy, Mar. 8, 2007, 14, pp. 775-780. |
Kinosita, Jr., et al., Formation and resealing of pores of controlled sizes in human erythrocyte membrane, Aug. 1977, vol. 268, pp. 438-441. |
Kirson et al., “Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors.” Proceedings of the National Academy of Sciences vol. 104, pp. 10152-10157 (2007). |
Knight, et al, Direct imaging of transvenous radiofrequency cardiac ablation using a steerable fiberoptic infrared endoscope, Heart Rhythm Society, Oct. 2005, vol. 2, No. 10, pp. 1116-1121. |
Kolb, J.F., et al., “Nanosecond pulsed electric field generators for the study of subcellular effects”, Bioelectromagnetics, 27(3): p. 172-187 (2006). |
Kotnik and Miklavcic, “Theoretical evaluation of voltage inducement on internal membranes of biological cells exposed o electric fields.” Biophysical Journal, vol. 90(2), pp. 480-491 (2006). |
Kotnik et al., “Sensitivity of transmembrane voltage induced by applied electric fields—A theoretical analysis”, Bioelectrochemistry and Bioenergetics, vol. 43, Issue 2, 1997, pp. 285-291. |
Kotnik, T. and D. Miklavcic, “Theoretical evaluation of the distributed power dissipation in biological cells exposed to electric fields”, Bioelectromagnetics, 21(5): p. 385-394 (2000). |
Kotnik, T., et al., “Cell membrane electropermeabilization by symmetrical bipolar rectangular pulses”. Part I. Increased efficiency of permeabilization. Bioelectrochemistry, 54(1): p. 83-90 (2001). |
Kotnik, T., et al., “Role of pulse shape in cell membrane electropermeabilization”, Biochimica Et Biophysica Acta-iomembranes, 1614(2): p. 193-200 (2003). |
Kotnik, T., et al., “Cell membrane electropermeabilization by symmetrical bipolar rectangular pulses. Part II. Reduced electrolytic contamination”, Bioelectrochemistry, 54(1): p. 91-95 (2001). |
Kranjc, M., S. Kranjc, F. Bajd, G. Sersa, I. Sersa, and D. Miklav{hacek over (c)}i{hacek over (c)}, “Predicting irreversible electroporation-induced tissue damage by means of magnetic resonance electrical impedance tomography,” Scientific reports, vol. 7, No. 1, pp. 1-10, 2017. |
Kroeger, et al, Curvature-driven pore growth in charged membranes during charge-pulse and voltage-clamp experiments, Biophysical Journal, Feb. 2009, 96, 3, pp. 907-916. |
Kurup, et al, Image-Guided Percutaneous Ablation of Bone and soft Tissue Tumors, Semin Intervent Radiol 2010, 27:276-284. |
Labeed et al., “Differences in the biophysical properties of membrane and cytoplasm of apoptotic cells revealed using dielectrophoresis.” Biochimica et Biophysica Acta (BBA)—General Subjects, vol. 1760, pp. 922-929 (2006). |
Lackovic, I., et al., “Three-dimensional Finite-element Analysis of Joule Heating in Electrochemotherapy and in vivo Gene Electrotransfer”, Ieee Transactions on Dielectrics and Electrical Insulation, 16(5): p. 1338-1347 (2009). |
Laufer, et al., Electricai impedance characterization of normal and cancerous human hepatic tissue, Physicological Measurement, vol. 31, pp. 995-1009 (2010). |
Lavee, et al., “A Novel Nonthermal Energy Source for Surgical Epicardial Atrial Ablation: Irreversible Electroporation,” The Heart Surgery Forum #2006-1201, vol. 10 (2): 96-101 (2007). |
Lebar et al., “Inter-pulse interval between rectangular voltage pulses affects electroporation threshold of artificial lipid bilayers.” IEEE Transactions on Nano Bioscience, vol. 1 (2002) pp. 116-120. |
Lee, Cassinian Oval, Nov. 2004, Mathematics Department of the University of California at Irvine, pp. 1-5. |
Lee, E. W. et al. Advanced Hepatic Ablation Technique for Creating Complete Cell Death : Irreversible Electroporation. Radiology 255, 426-433, doi:10.1148/radiol. 10090337 (2010). |
Lee, et al, Imaging guided percutaneous irreversible electroporation: Ultrasound and immunohistological correlation, Technology in Cancer Research and Treatment, Aug. 2007, vol. 6, No. 4, pp. 287-293. |
Lee, et al, Irreversible electroporation: A novel image-guided cancer therapy, Gut and Liver, Sep. 2010, vol. 4, Supp. 1, pp. S99-S104. |
Lee, R. C., D. J. Canaday, and S. M. Hammer. Transient and stable ionic permeabilization of isolated skeletal muscle cells after electrical shock. J. Burn Care Rehabil. 14:528-540,1993. |
Li, et al, The effects of irreversible electroporation (IRE) on nerves, PLOS One, Apr. 14, 2011, vol. 6, Iss. 4, e18831, pp. 1-7. |
Lin, et al., An optically induced cell lysis device using dielectrophoresis, Applied Physics Letters, Jan. 20, 2009, 94, 033901, pp. 1-3. |
Lion, et al, Poly(I:C) enhances the susceptibility of leukemic cells to NK cell cytotoxicity and phagocytosis by DC, PLOS One, vol. 6, Iss. 6, e20952, pp. 1-10, Jun. 17, 2011. |
Long, G., et al., “Targeted Tissue Ablation With Nanosecond Pulses”, Ieee Transactions on Biomedical Engineering, 58(8) (2011). |
Lu, et al, Irreversible electroporation: Ready for prime time?, Techniques in Vascular and Interventional Radiology, 2013, 16, pp. 277-286. |
Ivorra, A., ed. “Tissue Electroporation as a Bioelectric Phenomenon: Basic Concepts. Irreversible Electroporation”, ed. B. Rubinsky., Springer Berlin Heidelberg. 23-61 (2010). |
M. Marty et al., “Electrochemotherapy—An easy, highly effective and safe treatment of cutaneous and subcutaneous metastases: Results of ESOPE (European Standard Operating Procedures of Electrochemotherapy) study,” European Journal of Cancer Supplements, 4, pp. 3-13, 2006. |
Macek Lebar and Miklavcic, “Cell electropermeabilization to small molecules in vitro: control by pulse parameters.” Radiology and Oncology, vol. 35(3), pp. 193-202 (2001). |
Machado-Aranda, et al, Gene transfer of the Na+, K+K-ATPase B1 subunit using electroporation increases lung liquid clearance, American Journal of Respiratory and Critical Care Medicine, 2004, vol. 171, pp. 204-211. |
Macherey, O. et al., “Asymmetric pulses in cochlear implants: Effects of pulse shape, polarity, and rate,” JARO—J. Assoc. Res. Otolaryngol., vol. 7, No. 3, 253-266, 2006, 14 pages. |
Mahmood, F., et al., “Diffusion-Weighted MRI for Verification of Electroporation-Based Treatments”, Journal of Membrane Biology 240:131-138 (2011). |
Mahmood, Gehl, Optimizing clinical performance and geometrical robustness of a new electrode device for ntracranial tumor electroporation, Bioelectrochemistry, Jan. 6, 2011, 81, pp. 10-16. |
Mahnic-Kalamiza, et al., “Educational application for visualization and analysis of electric field strength in multiple electrode electroporation,” BMC Med Educ, vol. 12:102,13 pages, 2012. |
Mali, et al., “The Effect of Electroporation Pulses on Functioning of the Heart,” Med Biol Eng Comput (2008) 46:745-757. |
Malpica et al., “Grading ovarian serous carcinoma using a two-tier system.” The American Journal of Surgical Pathology, vol. 28, pp. 496-504 (2004). |
Maor et al., The Effect of Irreversible Electroporation on Blood Vessels, Tech, in Cancer Res. and Treatment, vol. 6, No. 4, Aug. 2007, pp. 307-312. |
Maor, et al, Intravascular irreversible electroporation: Theoretical and experimental feasibility study, 30th Annual International IEEE EMBS Conference, IEEE, Aug. 20, 2008, pp. 2051-2054. |
Maor, et al, Irreversible electroporation attenuates neointimal formation after angioplasty, IEEE Transactions on Biomedical Engineering, Sep. 2008, vol. 55, No. 9, pp. 2268-2274. |
Maor, et al., Non Thermal Irreversible Electroporation: Novel Technology for Vascular Smooth Muscle Cells Ablation, PLoS One, Mar. 2009, 4(3): p. e4757, 9 pages. |
Maor, Rubinsky, Endovascular nonthermal irreversible electroporation: A finite element analysis, Journal of Biomedical Engineering, Feb. 7, 2010, vol. 132, 031008, pp. 1-7. |
Marszalek et al., “Schwan equation and transmembrane potential induced by alternating electric field.” Biophysical Journal, vol. 58, pp. 1053-1058 (1990). |
Martin et al., “Gene Transfer to Intact Mesenteric Arteries by Electroporation” Journal of Vascular Research, 37:372-380 (2000). |
Martin, n.R.C.G., et al., “Irreversible electroporation therapy in the management of locally advanced pancreatic adenocarcinoma.” Journal of the American College of Surgeons, 2012.215(3): p. 361-369. |
Martinsen, O. G. and Grimnes, S., Bioimpedance and bioelectricity basics. Academic press, 2011. |
Maybody, An Overview of Image-Guided Percutaneous Ablation of Renal Tumors, Seminars in Interventional Radiology/vol. 27, No. 3, 2010, pp. 261-267. |
Mazurek, et al, Effect of Short HV Pulses in Bacteria and Fungi, 1995, vol. 2, No. 3, pp. 418-425. |
McCall, Nanoknife, liposomal doxorubicin show efficacy against liver cancer, European Congress of Radiology, Mar. 1, 2011, pp. 1-2. |
Abiror, I.G., et al., “Electric Breakdown of Bilayer Lipid-Membranes .1. Main Experimental Facts and Their Qualitative Discussion”, Bioelectrochemistry and Bioenergetics, 6(1): p. 37-52 (1979). |
Adeyanju, et al, The improvement of irreversible electroporation therapy using saline-irrigated electrodes: A theoretical study, Technology in Cancer Research and Treatment, Aug. 2011, vol. 10, No. 4, pp. 347-360. |
Agerholm-Larsen, B., et al., “Preclinical Validation of Electrochemotherapy as an Effective Treatment for Brain Trumors”, Cancer Research 71: 3753-3762 (2011). |
Al-Khadra, et al, The role of electroporation in defibrillation, Circulation Research, Oct. 27, 2000, 87, pp. 797-804. |
Al-Sakere et al., “Tumor ablation with irreversible electroporation.” PLoS One, Issue 11, e1135, 8 pages, 2007. |
Al-Sakere, et al, A study of the immunological response to tumor ablation with irreversible electroporation, Technology in Cancer Research and Treatment, Aug. 2007, vol. 6, No. 4, pp. 301-305. |
Albright, et al, Performance and complicatioins associated with the Synchromed 10-ml infusion pump for intrathecal baclofen administration in children, J Neurosurg (Pediatrics 2), Aug. 2004, vol. 101, pp. 64-68. |
Alinezhadbalalami, N. et al., “Generation of Tumor-activated T cells Using Electroporation”, Bioelectrochemistry 142 (2021) 107886, Jul. 13, 2021, 11 pages. |
Appelbaum et al., “US Findings after Irreversible Electroporation Ablation: Radiologic-Pathologic Correlation,” Radiology, 262, pp. 117-125, Jan. 1, 2012. |
Arena et al. “High-Frequency Irreversible Electroporation (H-FIRE) for Non-thermal Ablation without Muscle Contraction.” Biomed. Eng. Online, vol. 10, 20 pages (2011). |
Arena, C. B. et al., “Theoretical Considerations of Tissue Electroporation With High-Frequency Bipolar Pulses,” IEEE Trans. Biomed. Eng., vol. 58, No. 5, 1474-1482, 2011, 9 pages. |
Arena, C.B., et al., “A three-dimensional in vitro tumor platform for modeling therapeutic irreversible electroporation.” Biophysical Journal, 2012.103(9): p. 2033-2042. |
Arena, Christopher B., et al.,“Phase Change Electrodes for Reducing Joule Heating During Irreversible Electroporation”. Proceedings of the ASME 2012 Summer Bioengineering Conference, SBC2012, Jun. 20-23, 2012, Fajardo, Puerto Rico. |
Arena, et al, Theoretical considerations of tissue electropration with high frequency biopolar pulses, IEEEE, pp. 1-7, (2010). |
Arena, et al, Towards the development of latent heat storage electrodes for electroporation-based therapies, Applied Physics Letters, 2012, 101, 083902, pp. 1-4. |
Asami et al., “Dielectric properties of Aouse lyAphocytes and erythrocytes.” BiochiAica et Biophysica Acta (BBA)—Molecular Cell Research, 1010 (1989) pp. 49-55. |
Bolland, F., et al., “Development and characterisation of a full-thickness acellular porcine bladder matrix for tissue engineering”, Biomaterials, Elsevier Science Publishers, Barking, GB, vol. 28, No. 6,Nov. 28, 2006, pp. 1061-1070. |
Bagla, S. and Papadouris, D., “Percutaneous Irreversible Electroporation of Surgically Unresectable Pancreatic Cancer: A Case Report” J. Vascular Int. Radiol. 23(1), 142-145 (2012). |
Ball, et al, Irreversible electroporation: A new challenge in “out of the operating theater” anesthesia, Anesth Analg, May 2010, 110, pp. 1305-1309. |
Bancroft, et al., Design of a Flow Perfusion Bioreactor SysteA for Bone Tissue-Engineering Applications, Tissue Engineering, vol. 9, No. 3, 2003, p. 549-554. |
Baptista et al., “The Use of Whole Organ Decellularization for the Generation of a Vascularized Liver Organoid,” Heptatology, vol. 53, No. 2, pp. 604-617 (2011). |
Bayazitoglu, et al, An overview of nanoparticle assisted laser therapy, International Journal of Heat and Mass Transfer, Sep. 11, 2013, 67, pp. 469-486. |
Beebe, S.J., et al., “Diverse effects of nanosecond pulsed electric fields on cells and tissues”, DNA and Cell Biology, 22(12): 785-796(2003). |
Beebe, S.J., et al.,, “Nanosecond, high-intensity pulsed electric fields induce apoptosis in human cells”, FASEB J, 17(9): p. 1493-5 (2003). |
Beitel-White, N., S. Bhonsle, R. Martin, and R. V. Davalos, “Electrical characterization of human biological tissue or irreversible electroporation treatments,” in 2018 40th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC). IEEE, 2018, pp. 4170-4173. |
Belehradek, J., et al., “Electropermeabilization of Cells in Tissues Assessed by the Qualitative and Quantitative Electroloading of Bleomycin”, Biochimica Et Biophysica Acta—Biomembranes, 1190(1): p. 155-163 (1994). |
Ben-David, E. et al., “Irreversible Electroporation: Treatment Effect is Susceptible to Local Environment and Tissue Properties,” Radiology, vol. 269, No. 3, 2013, 738-747. |
Ben-David, E.,et al., “Characterization of Irreversible Electroporation Ablation in In Vivo Procine Liver” Am. J. Roentgenol. 198(1), W62-W68 (2012). |
Benz, R., et al. “Reversible electrical breakdown of lipid bilayer membranes: a charge-pulse relaxation study”. J Membr Biol, 48(2): p. 181-204 (1979). |
Bertacchini, et al, Design of an irreversible electroporation system for clinical use, Technology in Cancer Research and Treatment, Aug. 2007, vol. 6, No. 4, pp. 313-320. |
Bhonsle, S. et al., “Characterization of Irreversible Electroporation Ablation with a Validated Perfused Organ Model,” J. Vase. Interv. Radiol., vol. 27, No. 12, pp. 1913-1922.e2, 2016. |
Bhonsle, S. P. et al., “Mitigation of impedance changes due to electroporation therapy using bursts of high-frequency bipolar pulses,” Biomed. Eng. (NY)., vol. 14, No. Suppl 3, 14 pages, 2015. |
Bhonsle, S., M. F. Lorenzo, A. Safaai-Jazi, and R. V. Davalos, “Characterization of nonlinearity and dispersion in issue impedance during high-frequency electroporation,” IEEE Transactions on Biomedical Engineering, vol. 65, No. 10, pp. 2190-2201,2018. |
Bonakdar, M., E. L. Latouche, R. L. Mahajan, and R. V. Davalos, “The feasibility of a smart surgical probe for verification of IRE treatments using electrical impedance spectroscopy,” IEEE Trans. Biomed. Eng., vol. 62, No. 11, pp. 2674-2684, 2015. |
Bondarenko, A. and G. Ragoisha, Eis spectrum analyser (the program is available online at http://www.abc.chemistry.bsu.by/vi/analyser/. |
Boone, et al, Review imaging with electricity: Report of the European concerted action on impedance tomography, Journal of Medical Engineering & Technology, Nov. 1997, vol. 21, No. 6, pp. 201-232. |
Boussetta, N., N. Grimi, N. I. Lebovka, and E. Vorobiev, “Cold” electroporation in potato tissue induced by pulsed electric field, Journal of food engineering, vol. 115, No. 2, pp. 232-236,2013. |
Bower et al., “Irreversible electroporation of the pancreas: definitive local therapy without systemic effects.” Journal of surgical oncology, 2011.104(1): p. 22-28. |
Buist et al., “Efficacy of multi-electrode linear irreversible electroporation,” Europace, vol. 23, No. 3, pp. 464-468, 2021, 5 pages. |
Bulvik, B. E. et al. “Irreversible Electroporation versus Radiofrequency Ablation: A Comparison of Local and Systemic Effects in a Small Animal Model,” Radiology, vol. 280, No. 2, 2016,413-424. |
Butikofer, R. et al., “Electrocutaneous Nerve Stimulation-I: Model and Experiment,” IEEE Trans. Biomed. Eng., vol. BME-25, No. 6, 526-531, 1978,6 pages. |
Butikofer, R. et al., “Electrocutaneous Nerve Stimulation-II: Stimulus Waveform Selection,” IEEE Trans. Biomed. Eng., vol. BME-26, No. 2, 69-75, 1979. |
Cannon et al., “Safety and early efficacy of irreversible electroporation for hepatic tumors in proximity to vital structures.” Journal of Surgical Oncology, 6 pages (2012). |
Carmi, and Georgiades, Combination percutaneous and intraarterial therapy for the treatment of hepatocellular carcinoma: A review, Seminars in Interventional Radiology, 2010, vol. 27, No. 3, pp. 296-301. |
Carpenter A.E. et al., “CellProfiler: image analysis software for identifying and quantifying cell phenotypes.” Genome Biol. 2006; 7(10): R100. Published online Oct. 31, 2006,11 pages. |
Castellvi, Q., B. Mercadal, and A. Ivorra, “Assessment of electroporation by electrical impedance methods,” in Handbook of electroporation. Springer-Verlag, 2016, pp. 671-690. |
Cemazar M, Parkins CS, Holder AL, Chaplin DJ, Tozer GM, et al., “Electroporation of human microvascular endothelial cells: evidence for an anti-vascular mechanism of electrochemotherapy”, Br J Cancer 84: 565-570 (2001). |
Chang, D.C., “Cell Poration and Cell-Fusion Using an Oscillating Electric-Field”. Biophysical Journal, 56(4): p. 641-652(1989). |
Charpentier, et al, Irreversible electroporation of the liver an dliver hilum in swine, HBP, 2011, 13, pp. 168-173. |
Charpentier, K.P., et al., “Irreversible electroporation of the pancreas in swine: a pilot study.” HPB: the official journal of the International Hepato Pancreato Biliary Association, 2010.12(5): p. 348-351. |
PCT Application No. PCT/US2011/062067, International Search Report and Written Opinion dated Jul. 25, 2012. |
PCT Application No. PCT/US2011/066239, International Search Report (dated Aug. 22, 2012), and Written Opinion (dated Aug. 22, 2012). |
PCT International Search Report and Written Opinion from PCT/US2010/053077, dated Aug. 2, 2011. |
PCT International Search Report for PCT/US10/29243 dated Jul. 30, 2010, 4 pages. |
Pech, et al, Irreversible electroporation of renal cell carcinoma: A first-in-man phase I clinical study, Cardiovasc Intervent Radiol, Aug. 15, 2010. |
Persichetti F et al, “Normal and Expanded Huntington's Disease Gene Alleles Produce Distinguishable Proteins Due to Translation Across the CAG Repeat”, Molecular Medicine, Feinstein Institute for Medical Research, Washington, DC; US, (May 1, 1995), vol. 1, No. 4, ISSN 1076-1551, pp. 374-383, XP000997528. |
Philips, IntelliVue Patient Monitor, Jan. 2008, Philips, pp. 1-532 (Year: 2008). |
Phillips, et al, Irreversible electroporation on the small intestine, British Journal of Cancer, 2012, pp. 1-6. |
Phillips, et al, Nonthermal irreversible electroporation for tissue decellularization, Journal of Biomedical Engineering, Aug. 16, 2010, vol. 132, 091003, pp. 1-8. |
Polajzer, T. et al., “Cancellation effect is present in high-frequency reversible and irreversible electroporation,” Bioelectrochemistry, vol. 132, 2020, 11 pages. |
Polak, et al, On the electroporation thresholds of lipid bilayers: Molecular dynamics simulation investigations, J Membrane Biol, Jun. 13, 2013, 246, pp. 843-850. |
Pucihar et al., “Numerical determination of transmembrane voltage induced on irregularly shaped cells.” Annals of Biomedical Engineering, vol. 34, pp. 642-652 (2006). |
Qiao et al. Electrical properties of breast cancer cells from impedance measurement of cell suspensions, 2010, Journal of Physics, 224, 1-4 (2010). |
Radeva, et al, Induction of apoptosis and necrosis in cancer cells by electric fields, electromagnetic fields, and photodynamically active quinoids, Electromagnetic Biology and Medicine, 2003, 23, pp. 185-200. |
Rajagopal, V. and S.G. Rockson, Coronary restenosis: a review of mechanisms and management, The American Journal of Medicine, 2003, 115(7): p. 547-553. |
Rebersek, et al., Advantages and disadvantages of different concepts of electroporation pulse generation, Automatika, 2011, 52, 1, pp. 12-19. |
Reilly, J. P. et al., “Sensory Effects of Transient Electrical Stimulation-Evaluation with a Neuroelectric Model,” IEEE Trans. Biomed. Eng., vol. BME-32, No. 12, 1001-1011, 1985, 11 pages. |
Ringel-Scaia, V. M. et al., High-frequency irreversible electroporation is an effective tumor ablation strategy that induces immunologic cell death and promotes systemic anti-tumor immunity. EBioMedicine, 2019,44,112-125. |
Rogers, W. R. et al., “Strength-duration curve an electrically excitable tissue extended down to near 1 nanosecond,” IEEE Trans. Plasma Sci., vol. 32, No. 4 II, 1587-1599, 2004, 13 pages. |
Ron et al., “Cell-based screening for membranal and cytoplasmatic markers using dielectric spectroscopy.” Biophysical chemistry, 135 (2008) pp. 59-68. |
Rossmeisl et al., “Pathology of non-thermal irreversible electroporation (N-TIRE)-induced ablation of the canine brain.” Journal of Veterinary Science vol. 14, pp. 433-440 (2013). |
Rossmeisl, “New Treatment Modalities for Brain Tumors in Dogs and Cats.” Veterinary Clinics of North America: Small Animal Practice 44, pp. 1013-1038 (2014). |
Rossmeisl, John H. et al. Safety and feasibility of the NanoKnife system for irreversible electroporation ablative treatment of canine spontaneous intracranial gliomas. J. Neurosurgery 123.4 (2015): 1008-1025. |
Rowland, et al, Transvenous ablation of atrioventricular conduction with a low energy power source, Br Heart J, 1989, 62, pp. 361-366. |
Rubinsky, B., “Irreversible Electroporation in Medicine”, Technology in Cancer Research and Treatment, vol. 6, No. 4, Aug. 1, 2007, pp. 255-259. |
Rubinsky, et al, Optimal parameters for the destruction of prostate cancer using irreversible electroporation, The Journal of Urology, Dec. 2008, vol. 180, pp. 2668-2674. |
Rubinsky, L. et al., “Electrolytic Effects During Tissue Ablation by Electroporation,” Technol. Cancer Res. Treat., vol. 15, No. 5, NP95-103, 2016, 9 pages. |
Sabuncu, et al, Dielectrophoretic separation of mouse melanoma clones, Biomicrofluidics, Jun. 16, 2010, 4, 021101, pp. 1-7. |
SAI Infusion Technologies, “Rabbit Ear Vein Catheters”, https://www.sai-infusion.com/products/rabbit-ear-catheters, Aug. 10, 2017 webpage printout, 5 pages. |
Saldanha, et al, Current tumor ablation technologies: Basic science and device review, Seminars in Interventional Radiology, 2010, vol. 27, No. 3, pp. 247-254. |
Salford, L.G., et al., “A new brain tumour therapy combining bleomycin with in vivo electropermeabilization”, Biochem. Biophys. Res. Commun., 194(2): 938-943 (1993). |
Salmanzadeh et al., “Investigating dielectric properties of different stages of syngeneic murine ovarian cancer cells” Biomicrofiuidics 7, 011809 (2013), 12 pages. |
Salmanzadeh et al., “Sphingolipid Metabolites Modulate Dielectric Characteristics of Cells in a Mouse Ovarian Cancer Progression Model.” Integr. Biol., 5(6). pp. 843-852 (2013). |
Salmanzadeh et al.,“Dielectrophoretic differentiation of mouse ovarian surface epithelial cells, macrophages, and fibroblasts using contactless dielectrophoresis.” Biomicrofluidics, vol. 6,13 Pages (2012). |
Sanchez, B., G. Vandersteen, R. Bragos, and J. Schoukens, “Basics of broadband impedance spectroscopy measurements using periodic excitations,” Measurement Science and Technology, vol. 23, No. 10, p. 105501, 2012. |
Sanchez, B., G. Vandersteen, R. Bragos, and J. Schoukens, “Optimal multisine excitation design for broadband electrical impedance spec-troscopy,” Measurement Science and Technology, vol. 22, No. 11, p. 115601,2011. |
Sanders, et al., Nanosecond pulse generator with scalable pulse amplitude, IEEE, 2008, pp. 65-68. |
Sankaranarayanan, et al, Effect of irreversible electroporation on cell proliferation in fibroblasts, Proc. ESA Annual Meeting on Electrostatics, 2011, pp. 1-8. |
Sano et al., “In-vitro bipolar nano- and microsecond electro-pulse bursts for irreversible electroporation therapies.” Bioelectrochemistry vol. 100, pp. 69-79 (2014). |
Sano et al., “Modeling and Development of a Low Frequency Contactless Dielectrophoresis (cDEP) Platform to Sort cancer Cells from Dilute Whole Blood Samples.” Biosensors & Bioelectronics, 8 pages (2011). |
Sano et al., “Contactless Dielectrophoretic Spectroscopy: Examination of the Dielectric Properties of Cells Found in Blood.” Electrophoresis, 32, pp. 3164-3171, 2011. |
Sano, et al, Towards the creation of decellularized organ constructs using irreversible electroporation and active mechanical perfusion, Biomedical Engineering Online, 2010, 9, 83, pp. 1-16. |
Sano, M. B. et al., “Reduction of Muscle Contractions During Irreversible Electroporation Therapy Using High-Frequency Bursts of Alternating Polarity Pulses: A Laboratory Investigation in an Ex Vivo Swine Model,” J. Vase, interv. Radiol., vol. 29, No. 6, 893-898.e4, Jun. 2018, 18 pages. |
Sano, M. B. et al., “Burst and continuous high frequency irreversible electroporation protocols evaluated in a 3D tumor Model,” Phys. Med. Biol., vol. 63, No. 13, 2018,17 pages. |
Saur et al., “CXCR4 expression increases liver and lung metastasis in a mouse model of pancreatic cancer.” Gastroenterology, vol. 129, pp. 1237-1250 (2005). |
Savader, et al.“Treatment of Hemodialysis Catheter-associated Fibrin Sheaths by rt-PA Infusion: Critical Analysis of 124 Procedures,” J Vasc Intery Radiol 2001; 12:711-715. |
Schoenbach et al., “Intracellular effect of ultrashort electrical pulses.” Bioelectromagnetics, 22 (2001) pp. 440-448. |
Schoenbach, et al, Bioelectric effects of intense nanosecond pulses, IEEE Transactions on Dielectric and Electrical Insulation, 2007, vol. 14, Iss. 5, pp. 1088-1109. |
Seibert et al., “Clonal variation of MCF-7 breast cancer cells in vitro and in athymic nude mice.” Cancer Research, vol. 13, pp. 2223-2239 (1983). |
Seidler et al., “A Cre-IoxP-based mouse model for conditional somatic gene expression and knockdown in vivo by using avian retroviral vectors.” Proceedings of the National Academy of Sciences, vol. 105, pp. 10137-10142 (2008). |
Chen et al., “Classification of cell types using a microfluidic device for mechanical and electrical measurement on single cells.” Lab on a Chip, vol. 11, pp. 3174-3181 (2011). |
Chen, et al, Preclinical study of locoregional therapy of hepatocellular carcinoma by bioelectric ablation with microsecond pulsed electric fields (usPEFs), Scientific Reports, Apr. 2015, 5, 9851, pp. 1-10. |
Chen, M.T., et al., “Two-dimensional nanosecond electric field mapping based on cell electropermeabilization”, PMC Biophys, 2(1 ):9 (2009). |
Choi, et al, Preclinical analysis of irreversible electroporation on rat liver tissues using a microfabricated electroporator, Tissue Engineering Part C, 2010, vol. 16, No. 6, pp. 1245-1253. |
Clark et al., “The electrical properties of resting and secreting pancreas.” The Journal of Physiology, vol. 189, pp. 247-260 (1967). |
Corovic, et al, Analytical and numerical quantification and comparison of the local electric field in the tissue for different electrode configurations, BioMedical Engineering Online, Oct. 15, 2007, 6, 37, pp. 1-14. |
Cosman, E. R. et al., “Electric and Thermal Field Effects in Tissue Around Radiofrequency Electrodes,” Pain Med., vol. 6, No. 6, 405-4124, 2005, 20 pages. |
Craiu, Scadden, Chapter 22 flow electroporation with pulsed electric fields for purging tumor cells, Electroporation Protocols: Preclinical and Clinical Gene Medicine, Methods in Molecular Biology, vol. 423, 2008, pp. 301-310. |
Creason, S. O, J. W. Hayes, and D. E. Smith, “Fourier transform faradaic admittance measurements iii. comparison pf measurement efficiency for various test signal waveforms,” Journal of Electroanalytical chemistry and interfacial electrochemistry, vol. 47, No. 1, pp. 9-46,1973. |
Cukjati, et al, Real time electroporation control for accurate and safe in vivo non-viral gene therapy, Bioelectrochemistry, Nov. 10, 2006, 70, pp. 501-507. |
Dahl et al., “Nuclear shape, mechanics, and mechanotransduction.” Circulation Research vol. 102, pp. 1307-1318 (2008). |
Daniels, Rubinsky, Electrical field and temperature model of nonthermal irreversible electroporation in heterogeneous tissues, Journal of Biomedical Engineering, Jul. 2009, vol. 131, 071006, pp. 1-12. |
Daniels, Rubinsky, Temperature modulation of electric fields in biological matter, PLOS One, vol. 6, Iss. 6, e20877, pp. 1-9, Jun. 2011. |
Daskalov, I., et al, “Exploring new instrumentation parameters for electrochemotherapy—Attacking tumors with bursts of biphasic pulses instead of single pulses”, IEEE Eng Med Biol Mag, 18(1): p. 62-66 (1999). |
Daud, A.I., et al., “Phase 1 Trial of Interleukin-12 Plasmid Electroporation in Patients With Metastatic Melanoma,” Journal of Clinical Oncology, 26, 5896-5903, Dec. 20, 2008. |
Davalos et al., “Electrical impedance tomography for imaging tissue electroporation,” IEEE Transactions on Biomedical Engineering, 51, pp. 761-767, 2004. |
Davalos, R. V. & Rubinsky, B. Temperature considerations during irreversible electroporation. International Journal of Heat and Mass Transfer 51, 5617-5622, doi:10.1016/j.ijheatmasstransfer.2008.04.046 (2008). |
De Senneville, B. D. et al., “MR thermometry for monitoring tumor ablation,” European radiology, vol. 17, No. 9, pp. 2401-2410, 2007. |
De Vuyst, E., et al., “In situ bipolar Electroporation for localized cell loading with reporter dyes and investigating gap functional coupling”, Biophysical Journal, 94(2): p. 469-479 (2008). |
Demirbas, M. F., “Thermal Energy Storage and Phase Change Materials: An Overview” Energy Sources Part B 1(1), 35-95 (2006). |
Deodhar, et al, Irreversible electroporation near the heart: Ventricular arrhythmias can be prevented with ECG synchronization, AJR, Mar. 2011, 196, pp. W330-W335. |
Deodhar, et al, Renal tissue ablation with irreversible electroporation: Preliminary results in a porcine model, Technology and Engineering, Urology, 2010, 1-7. |
Dev, et al, Electric field of a six-needle array electrode used in drug and DNA delivery in vivo: Analytical versus numerical solution, IEEE Transactions on Biomedical Engineering, Nov. 2003, vol. 50, No. 11, pp. 1296-1300. |
Diederich, et al, Catheter-based ultrasound applicators for selective thermal ablation: progress towards MRI-guided applications in prostate, Int. J. Hyperthermia, Nov. 2004, vol. 20, No. 7, pp. 739-756. |
Du Pre, et al, Minimal coronary artery damage by myocardial electroporation ablation, European Society of Cardiology, Europace, May 31, 2012, pp. 1-6. |
Duck, F. A., Physical Properties of Tissue: A Comprehensive Reference Book. London: Harcourt Brace Jovanovich, 1990. |
Dunki-Jacobs, et al, Evaluation of resistance as a measure of successful tumor ablation during irreversible electroporation of the pancreas, American College of Surgeons, Feb. 2014, vol. 218, No. 2, pp. 179-187. |
Dupuy, and Shulman, Current status of thermal ablation treatments for lung malignancies, Seminars in Interventional Radiology, 2010, vol. 27, No. 3, pp. 268-275. |
Dupuy, et al, Irreversible electroporation in a swine lung model, Cardiovasc Intervent Radiol, Dec. 30, 2010, 34, pp. 391-395. |
Edd, J.F, et al., 2007, “Mathematical modeling of irreversible electroporation fortreatment planning.”, Technology in Cancer Research and Treatment, 6:275-286. |
Ellis TL, Garcia PA, Rossmeisl JH, Jr., Henao-Guerrero N, Robertson J, et al., “Nonthermal irreversible electroporatior for intracranial surgical applications. Laboratory investigation”, J Neurosurg 114: 681-688 (2011). |
Eppich et al., “Pulsed electric fields for selection of hematopoietic cells and depletion of tumor cell contaminants.” Nature Biotechnology 18, pp. 882-887 (2000). |
Ermolina et al., “Study of normal and malignant white blood cells by time domain dielectric spectroscopy.” IEEE Transactions on Dielectrics and Electrical Insulation, 8 (2001) pp. 253-261. |
Esser, A.T., et al., “Towards solid tumor treatment by irreversible electroporation: intrinsic redistribution of fields and currents in tissue”. Technol Cancer Res Treat, 6(4): p. 261-74 (2007). |
Esser, A.T., et al., “Towards Solid Tumor Treatment by Nanosecond Pulsed Electric Fields”, Technology in Cancer Research & Treatment, 8(4): p. 289-306 (2009). |
Faroja, et al, Irreversible electroporation ablation: Is all the damage nonthermal?, Radiology, Feb. 2013, vol. 266, No. 2, pp. 462-470. |
Fischbach, et al, Engineering tumors with 3D scaffolds, Nature Methods, Sep. 2, 2007, vol. 4, No. 10, pp. 855-860. |
Flanagan et al., “Unique dielectric properties distinguish stem cells and their differentiated progeny.” Stem Cells, vol. 26, pp. 656-665 (2008). |
Fong et al., “Modeling Ewing sarcoma tumors in vitro with 3D scaffolds.” Proceedings of the National Academy of Sciences vol. 110, pp. 6500-6505 (2013). |
Foster, R.S., et al., Production of Prostatic Lesions in Canines Using Transrectally Administered High-Intensity Focused Ultrasound. Eur. Urol., 1993; 23: 330-336. |
Frandsen, S. K., H. Gissel, P. Hojman, T. Tramm, J. Eriksen, and J. Gehl. Direct therapeutic applications of calcium electroporation to effectively induce tumor necrosis. Cancer Res. 72:1336-41,2012. |
Freeman, S.A., et al., Theory of Electroporation of Planar Bilayer-Membranes—Predictions of the Aqueous Area, Change in Capacitance, and Pore-Pore Separation. Biophysical Journal, 67(1): p. 42-56 (1994). |
Gabriel, C, Dielectric properties of biological tissue: variation with age. Bioelectromagnetics, 2005. Suppl 7: p. S12-8. |
Garca-Sánchez, T., A. Azan, I. Leray, J. Rosell-Ferrer, R. Bragos, and L. M. Mir, “Interpulse multifrequency electrical Impedance measurements during electroporation of adherent differentiated myotubes,” Bioelectrochemistry, vol. 105, pp. 123-135, 2015. |
Garcia et al., “Irreversible electroporation (IRE) to treat brain cancer.” ASME Summer Bioengineering Conference, Marco Island, FL, Jun. 25-29, 2008, 2 pages. |
Garcia et al., “Towards a Predictive Model of Electroporation-Based Therapies using Pre-Pulse Electrical Measurements” Abstract presented in the IEEE Engineering in Medicine and Biology Conference in Aug. 28, 2012 in San Diego, California, 4 pages. |
Garcia P.A., et al., “Pilot study of irreversible electroporation for intracranial surgery”, Conf Proc IEEE Eng Med Biol Soc, 2009:6513-6516, 2009. |
Garcia P.A., et al., “7.0-T Magnetic Resonance Imaging Characterization of Acute Blood-Brain-Barrier Disruption Achieved with Intracranial Irreversible Electroporation”, PLOS One, Nov. 2012, 7:11, e50482. |
Garcia, et al, A parametric study delineating irreversible electroporation from thermal damage based on a minimally invasive intracranial procedure, Biomedical Engineering Online, 2011, 10: 34, pp. 1-21. |
Garcia, et al, Irreversible electroporation (IRE) to treat brain tumors, Proceedings of the ASME 2008 Summer Bioengineering Conference (SBC2008), Jun. 25, 2008, pp. 6-7. |
McCarley, and Soulen, Percutaneous ablation of hepatic tumors, Seminars in Interventional Radiology, 2010, vol. 27, No. 3, pp. 255-260. |
McIntyre, C. C. et al., “Modeling the excitability of mammalian nerve fibers: Influence of afterpotentials on the recovery cycle,” J. Neurophysiol., vol. 87, No. 2, 995-1006, 2002, 12 pages. |
McNeal, D. R., “Analysis of a Model for Excitation of Myelinated Nerve,” IEEE Trans. Biomed. Eng., vol. BME-23, No. 4 329-337, 1976, 9 pages. |
McWilliams, et al, Image-guided tumor ablation: Emerging technologies and future directions, Seminars in Interventional Radiology, 2010, vol. 27, No. 3, pp. 302-313. |
Mercadal, B. et al., “Avoiding nerve stimulation in irreversible electroporation: A numerical modeling study,” Phys. Med. Biol., vol. 62, No. 20, 8060-8079, 2017, 28 pages. |
Miklav{hacek over (c)}i{hacek over (c)}, D. et al., “The effect of high frequency electric pulses on muscle contractions and antitumor efficiency in vivo or a potential use in clinical electrochemotherapy,” Bioelectrochemistry, vol. 65,121-128, 2004, 8 pages. |
Min, M., A. Giannitsis, R. Land, B. Cahill, U. Pliquett, T. Nacke, D. Frense, G. Gastrock, and D. Beckmann, Comparison of rectangular wave excitations in broad band impedance spectroscopy for microfluidic applications, in World Congress on Medical Physics and Biomedical Engineering, Sep. 7-12, 2009, Munich, Germany. Springer, 2009, pp. 85-88. |
Min, M., U. Pliquett, T. Nacke, A. Barthel, P. Annus, and R. Land, “Broadband excitation for short-time impedance spectroscopy,” Physiological measurement, vol. 29, No. 6, p. S185,2008. |
Mir et al., “Mechanisms of Electrochemotherapy” Advanced Drug Delivery Reviews 35:107-118 (1999). |
Mir et al., British Journal of Cancer, 77(12):2336-2342 (1998). |
Mir, Chapter 1 application of electroporation gene therapy: Past, current and future, Electroporation Protocols: Preclinical and Clinical Gene Medicine, Methods in Molecular Biology, vol. 423, 2008, pp. 3-17. |
Mir, Orlowski, Introduction: Electropermeabilization as a new drug delivery approach, Methods in Molecular Medicine, 2000, vol. 37, pp. 99-117. |
Mulhall et al., “Cancer, pre-cancer and normal oral cells distinguished by dielectrophoresis.” Analytical and Bioanalytical Chemistry, vol. 401, pp. 2455-2463 (2011). |
Nath, S., Dimarco, J. P. and Haines, D. E. (1994), Basic Aspects of Radiofrequency Catheter Ablation. Journal of Cardiovascular Electrophysiology, 5: 863-876. |
Neal II, et al, Experimental characterization and numerical modeling of tissue electrical conductivity during pulsed electric fields for irreversible electroporation treatment planning, IEEE Transactions on Biomedical Engineering, Apr. 2012, vol. 59, No. 4, pp. 1076-1085. |
Neal II, et al, Successful treatment of a large soft tissue sarcoma with irreversible electroporaiton, Journal of Clinical Oncology, May 1, 2011, vol. 29, No. 13, pp. e372-e377. |
Neal II, R. E. et al. In Vitro and Numerical Support for Combinatorial Irreversible Electroporation and Electrochemotherapy Glioma Treatment. Annals of Biomedical Engineering, Oct. 29, 2013,13 pages. |
Neal II, R.E., et al., “Treatment of breast cancer through the application of irreversible electroporation using a novel minimally invasive single needle electrode.” Breast Cancer Research and Treatment, 2010. 123(1): p. 295-301. |
Neal II et al., “Experimental Characterization and Numerical Modeling of Tissue Electrical Conductivity during Pulsed Electric Fields for Irreversible Electroporation Treatment Planning,” Biomedical Engineering, IEEE Transactions on Biomedical Engineering, vol. 59, pp. 1076-1085, 2012. |
Neal Re II, et al. (2013) Improved Local and Systemic Anti-Tumor Efficacy for Irreversible Electroporation in Immunocompetent versus Immunodeficient Mice. PLoS One 8(5): e64559. https://doi.org/10.1371/journal.pone.0064559. |
Neal, Davalos, The feasibility of irreversible electroporation for the treatment of breast cancer and other heterogeneous systems, Annals of Biomedical Engineering, Dec. 2009, vol. 37, No. 12, pp. 2615-2625. |
Neal, et al, A study using irreversible electroporation to treat large, irregular tumors in a canine patient, 32nd Annual International Conference of the IEEE EMBS, IEEE, Aug. 2010, pp. 2747-2750. |
Neal, et al, An “Off-the-Shelf” system for intraprocedural electrical current evaluation and monitoring of irreversible electroporation therapy, Cardiovasc Intervent Radiol, Feb. 27, 2014. |
Nesin et al., “Manipulation of cell volume and membrane pore comparison following single cell permeabilization with 60- and 600-ns electric pulses.” Biochimica et Biophysica Acta (BBA)—Biomembranes, vol. 1808, pp. 792-801 (2011). |
Neu, and Neu, Mechanism of irreversible electroporation in cells: Insight from the models, Irreversible Electroporation: Biomed, pp. 85-122. |
Neven et al., Epicardial Linear Electroporation Ablation and Lesion Size, Department of Cardiology, University of Medical Utrecht, Aug. 2014, vol. 11, No. 8. |
Nikolova, B., et al., “Treatment of Melanoma by Electroporation of Bacillus Calmette-Guerin”. Biotechnology & Biotechnological Equipment, 25(3): p. 2522-2524 (2011). |
Nikolski, et al., Electroporation of the heart, Europace, 2005, 7, pp. S146-S154. |
Nuccitelli, R., et al., “A new pulsed electric field therapy for melanoma disrupts the tumor's blood supply and causes complete remission without recurrence”, Int J Cancer, 125(2): p. 438-445 (2009). |
O'Brien, T. J. et al., “Effects of internal electrode cooling on irreversible electroporation using a perfused organ Model,” Int. J. Hyperth., vol. 35, No. 1, pp. 44-55, 2018. |
O'Brien et al., “Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity.” European Journal of Biochemistry, vol. 267, pp. 5421-5426 (2000). |
Ohio Environmental Protection Agency, Ground Water Flow and Fate and Transport Modeling, State of Ohio Environmental Protection Agency, 2007, pp. 14-1-14-32. |
Onik, and Rubinsky, Irreversible electroporation: First patient experience focal therapy of prostate cancer, Irreversible Electroporation, Biomed, pp. 235-247. |
Onik, et al, Irreversible electroporation: Implications for prostate ablation, Technology in Cancer Research and Treatment, Aug. 2007, vol. 6, No. 4, pp. 295-300. |
Onik, G. and B. Rubinsky, eds. “Irreversible Electroporation: First Patient Experience Focal Therapy of Prostate Cancer. Irreversible Electroporation”, ed. B. Rubinsky 2010, Springer Berlin Heidelberg, pp. 235-247. |
Onik, G.,P. Mikus, and B. Rubinsky, “Irreversible electroporation: implications for prostate ablation.” Technol Cancer Res Treat, 2007. 6(4): p. 295-300. |
Ott, H. C., et al., “Perfusion-decellularized matrix: using nature's platform to engineer a bioartificial heart”, Nature Medicine, Nature Publishing Group, New York, NY, US, vol. 14, No. 2,Feb. 1, 2008, pp. 213-221. |
Pakhomova, O. N., Gregory, B., Semenov 1., and Pakhomov, A. G., BBA—Biomembr., 2014, 1838, 2547-2554. |
Partridge, B. R. et al., “High-Frequency Irreversible Electroporation for treatment of Primary Liver Cancer: A Proof-of-Principle Study in Canine Hepatocellular Carcinoma,” J. Vasc. Interv. Radiol, vol. 31, No. 3, 482-491.e4, Mar. 2020, 19 pages. |
Paszek et al., “Tensional homeostasis and the malignant phenotype.” Cancer Cell, vol. 8, pp. 241-254 (2005). |
Pavseij, N. et al. The course of tissue permeabilization studied on a mathematical model of a subcutaneous tumor in small animals. IEEE Trans Biomed Eng 52,1373-1381 (2005). |
Pavselj, N., et al., “A numerical model of skin electroporation as a method to enhance gene transfection in skin. 11th Mediterranean Conference on Medical and Biological Engineering and Computing”, vols. 1 and 2, 16(1-2): p. 597-601 (2007). |
PCT Application No. PCT/US 19/51731 (VTIP-A1001-PCT), International Search Report and Written Opinion dated Feb. 20, 2020,19 pgs. |
PCT Application No. PCT/US09/62806, International Search Report (dated Jan. 19, 2010), Written Opinion (dated Jan. 19, 2010), and International Preliminary Report on Patentability (dated Jan. 4, 2010), 15 pgs. |
PCT Application No. PCT/US10/53077, International Search Report (dated Aug. 2, 2011), Written Opinion (dated Aug. 2, 2011), and International Preliminary Report on Patentability (dated Apr. 17, 2012). |
PCT Application No. PCT/US15/30429 (VTIP-97), International Search Report and Written Opinion dated Oct. 16, 2015,19 pages. |
PCT Application No. PCT/US15/65792, International Search Report (dated Feb. 9, 2016), Written Opinion (dated Feb. 9, 2016), and International Preliminary Report on Patentability (dated Jun. 20, 2017), 15 pages. |
PCT Application No. PCT/US2004/043477, International Search Report (dated Aug. 26, 2005), Written Opinion (dated Aug. 26, 2005), and International Preliminary Report on Patentability (dated Jun. 26, 2006). |
PCT Application No. PCT/US2009/042100, International Search Report (dated Jul. 9, 2009), Written Opinion (dated Jul. 9, 2009), and International Preliminary Report on Patentability (dated Nov. 2, 2010). |
PCT Application No. PCT/US2010/030629, International Search Report (dated Jul. 15, 2010), Written Opinion (dated Jul. 15, 2010), and International Preliminary Report on Patentability (dated Oct. 11, 2011). |
Garcia, et al, Non-thermal irreversible electroporation (N-TIRE) and adjuvant fractionated radiotherapeutic multimodal therapy for intracranial malignant glioma in a canine patient, Feb. 2011, vol. 10, No. 1, pp. 73-83. |
Garcia, et al, Non-thermal irreversible electroporation for deep intracranial disorders, 32nd Annual International Conference of the IEEE EMBS, IEEE, Aug. 2010, pp. 2747463. |
Garcia, et al, Position paper concerning the use of Angiodynamics' nanoknife system for treatment of brain gliomas, Virgina Tech—Wake Forest University, May 22, 2013, pp. 1-46. |
Garcia, P.A., et al., Intracranial Nonthermal Irreversible Electroporation: In Vivo Analysis. Journal of Membrane Biology, 2010. 236(1): p. 127-136. |
Garcia, P.A., R.V. Davalos, and D. Miklavcic, A Numerical Investigation of the Electric and Thermal Cell Kill Distributions in Electroporation-Based Therapies in Tissue. Plos One, 2014. 9(8). |
Garcia, Paulo A., Robert E. Neal IL and Rafael V. Davalos, Chapter 3, Non-Thermal Irreversible Electroporation for Tissue Ablation, In: Electroporation in Laboratory and Clinical Investigations ISBN 978-1-61668-327-6 Editors: Enrico P. Spugnini and Alfonso Baldi, 2010,22 pages. |
Gascoyne et al., “Membrane changes accompanying the induced differentiation of Friend murine erythroleukemia cells studied by dielectrophoresis.” Biochimica et Biophysica Acta (BBA)—Biomembranes, vol. 1149, pp. 119-126 (1993). |
Gawad, S., T. Sun, N. G. Green, and H. Morgan, “Impedance spectroscopy using maximum length sequences: Application to single cell analysis,” Review of Scientific Instruments, vol. 78, No. 5, p. 054301,2007. |
Gilbert, T. W., et al., “Decellularization of tissues and organs”, Biomaterials, Elsevier Science Publishers, Barking, GB, vol. 27, No. 19, Jul. 1, 2006, pp. 3675-3683. |
Gimsa, et al, Dielectric spectroscopy of single human erythrocytes at physiological ionic strength: Dispersion of the cytoplasm, Biophysical Journal, Jul. 1996, vol. 71, pp. 495-506. |
Golberg, A. and Rubinsky, B., “A statistical model for multidimensional irreversible electroporation cell death in tissue.” Biomed Eng Online, 9,13 pages, 2010. |
Gowrishankar et al., An Approach to electrical modeling of single and multiple cells, Mar. 18, 2003, PNAS, vol. 100 No. 6, pp. 3203-3208. |
Gowrishankar T.R., et al., “Microdosimetry for conventional and supra-electroporation in cells with organelles”. Biochem Biophys Res Commun, 341(4): p. 1266-76 (2006). |
Granot, Y., A. Ivorra, E. Maor, and B. Rubinsky, “In vivo imaging of irreversible electroporation by means of electrical impedance tomography,” Physics in Medicine & Biology, vol. 54, No. 16, p. 4927,2009. |
Groen, M. H. A. et al., “In Vivo Analysis of the Origin and Characteristics of Gaseous Microemboli during Catheter-Mediated Irreversible Electroporation,” Europace, 2021, 23(1), 139-146. |
Guenther, E. et al., “Electrical breakdown in tissue electroporation,” Biochem. Biophys. Res. Commun., vol. 467, No. 4, 736-741, Nov. 2015, 15 pages. |
Guo, et al, Irreversible electroporation in the liver: Contrast-enhanced inversion-recovery MR imaging approaches to differentiate reversibly electroporated penumbra from irreversibly electroporated ablation zones, Radiology, Feb. 2011, vol. 258, No. 2, pp. 461-468. |
Hall, et al, Nanosecond pulsed electric fields have differential effects on cells in the S-phase, DNA and Cell Biology, 2007, vol. 26, No. 3, pp. 160-171. |
Hall, et al, Nanosecond pulsed electric fields induce apoptosis in p53-wildtype and p53-null HCT116 colon carcinoma cells, Apoptosis, May 23, 2007, 12, pp. 1721-1731. |
Hasgall, P. et al., “IT'IS Database for thermal and electromagnetic parameters of biological tissues,” 2018, it is.swiss/database%0A%0A. |
He, et al, Nonlinear current response of micro electroporation and resealing dynamics for human cancer cells, Bioelectrochemistry, Jan. 29, 2008, 72, pp. 161-168. |
Helczynska et al., “Hypoxia promotes a dedifferentiated phenotype in ductal breast carcinoma in situ.” Cancer Research, vol. 63, pp. 1441-1444 (2003). |
Hjouj, et al, MRI study on reversible and irreversible electroporation induced blood brain barrier disruption, Aug. 10, 2012, PLOS One, vol. 7, 8, e42817, pp. 1-9. |
Hjouj, M., et al., “MRI Study on Reversible and Irreversible Electroporation Induced Blood Brain Barrier Disruption”, PLOS One, Aug. 2012, 7:8, e42817. |
Hjouj, Mohammad et al., “Electroporation-Induced BBB Disruption and Tissue Damage Depicted by MRI,” Abstracts from 16th Annual Scientific Meeting of the Society for Neuro-Oncology in Conjunction with the AANS/CNS Section on Tumors, Nov. 17-20, 2011, Orange County California, Neuro-Oncology Supplement, vol. 13, Supplement 3, p. iii114. |
Hoejholt, K. L. et al. Calcium electroporation and electrochemotherapy for cancer treatment: Importance of cell Tiembrane composition investigated by lipidomics, calorimetry and in vitro efficacy. Scientific Reports (Mar. 18, 2019) 3:4758, p. 1-12. |
Hong, et al, Cardiac ablation via electroporation, 31st Annual International Conference of the IEEE EMBS, IEEE, Sep. 2, 2009, pp. 3381-3384. |
Hu, Q., et al., “Simulations of transient membrane behavior in cells subjected to a high-intensity ultrashort electric pulse”, Physical Review E, 71(3) (2005). |
Ibey et al., “Selective cytotoxicity of intense nanosecond-duration electric pulses in mammalian cells.” Biochimica Et Biophysica Acta—General Subjects, vol. 1800, pp. 1210-1219 (2010). |
International Application No. PCT/US2009/042100, International Search Report dated Jul. 9, 2009, 5 pages. |
International Search Report 06751655_SESR dated Oct. 16, 2009. |
International Search Report 07716249_SESR dated Jan. 19, 2009. |
International Search Report 09739678_SESR dated May 3, 2012. |
International Search Report 12002108_EPS dated May 30, 2012. |
International Search Report 12002108.4 ESO dated Jun. 12, 2013. |
International Search Report for 06751655 SESR dated Oct. 9, 2016. |
International Search Report for 06751655.9 ESO dated Oct. 29, 2009. |
International Search Report for 10824248.8 ESO dated Jan. 20, 2014. |
International Search Report for 11833421 SESR dated Mar. 18, 2014. |
International Search Report for IPRP, PCT/US2006/01645, dated Oct. 30, 2007, 5 pages. |
International Search Report for PCT-US-10-053077 ISR dated Aug. 2, 2011. |
International Search Report for PCT-US-10-053077 WOSA dated Aug. 2, 2011. |
International Search Report for PCT/US06/16045 ISR dated Sep. 25, 2007, 1 page. |
International Search Report for PCT/US2006/016045 IPRP dated Oct. 30, 2007. |
International Search Report for PCT/US2007/000084 IPRP dated Jul. 8, 2008, 8 pages. |
International Search Report for PCT/US2009/038661 IPRP dated Sep. 28, 2010. |
International Search Report for PCT/US2009/042100 IPRP dated Nov. 2, 2010. |
International Search Report for PCT/US2009/042100 WOSA dated Jul. 9, 2009. |
International Search Report for PCT/US2009/047969 IPRP dated Dec. 21, 2010. |
International Search Report for PCT/US2009/047969 ISR dated Jan. 21, 2010. |
International Search Report for PCT/US2009/047969 WOSA dated Jan. 21, 2010. |
International Search Report for PCT/US2009/048270 IPRP dated Jan. 5, 2011. |
International Search Report for PCT/US2009/048270 ISR dated Feb. 11, 2010. |
International Search Report for PCT/US2009/048270 WOSA dated Feb. 11, 2010. |
International Search Report for PCT/US2009/062806 WOSA dated Jan. 19, 2010. |
International Search Report for PCT/US2010/022011 IPRP dated Jul. 26, 2011. |
International Search Report for PCT/US2010/022011 ISR dated Aug. 30, 2010. |
International Search Report for PCT/US2010/022011 WOSA dated Aug. 30, 2010. |
International Search Report for PCT/US2010/029243 IPRP dated Oct. 4, 2011. |
International Search Report for PCT/US2010/029243 WOSA dated Jul. 30, 2010. |
International Search Report for PCT/US2010/036734 IPRP dated Nov. 29, 2011. |
International Search Report for PCT/US2010/036734 ISR dated Dec. 23, 2010. |
International Search Report for PCT/US2010/036734 WOSA dated Dec. 23, 2010. |
International Search Report for PCT/US2010/053077 IPRP dated Apr. 17, 2012. |
International Search Report for PCT/US2011/024909 IPRP dated Aug. 21, 2012. |
International Search Report for PCT/US2011/024909 ISR dated Oct. 18, 2011. |
International Search Report for PCT/US2011/024909 WOSA dated Oct. 18, 2011. |
International Search Report for PCT/US2011/025003 IPRP dated Aug. 21, 2012. |
International Search Report for PCT/US2011/025003 ISR dated Oct. 24, 2011. 10 pages. |
International Search Report for PCT/US2011/025003 WOSA dated Oct. 24, 2011. |
International Search Report for PCT/US2011/056177 ESO dated Mar. 28, 2014. |
International Search Report for PCT/US2011/056177 IPRP dated Apr. 16, 2013. |
International Search Report for PCT/US2011/056177 ISR dated May 30, 2012. |
International Search Report for PCT/US2011/056177 WOSA dated May 30, 2012. |
International Search Report for PCT/US2011/062067 IPRP dated May 28, 2013. |
International Search Report for PCT/US2011/062067 ISR dated Jul. 25, 2012. |
International Search Report for PCT/US2011/062067 WOSA dated Jul. 25, 2012. |
International Search Report for PCT/US2015/065792 dated Feb. 9, 2016. |
International Search Report PCT-US-07-000084 ISR dated Dec. 14, 2007, 2 pages. |
International Search Report PCT/US07/00084 WOSA dated Dec. 14, 2007, 7 pages. |
International Search Report PCT/US2009/038661 ISR dated Jun. 12, 2009. |
International Search Report PCT/US2009042100 ESO dated May 11, 2012. |
Issa, et al, Recent Reports: The TUNA procedure for BPH: Review of the technology, Infections in Urology, Jul. 1998, 8 pages. |
Issa, et al, Specialty Surgery: The TUNA procedure for BPH: Basic procedure and clinical results, Infections in Urology, Sep. 1998, 6 pages. |
Ivey, J_ W., E. L. Latouche, M. B. Sano, J_ H. Rossmeisl, R. V. Davalos, and S. S. Verbridge, “Targeted cellular ablation based on the morphology of malignant cells,” Sci. Rep., vol. 5, pp. 1-17, 2015. |
Ivorra et al., “In vivo electric impedance measurements during and after electroporation of rat live.” Bioelectrochemistry, vol. 70, pp. 287-295 (2007). |
Ivorra, et al, In vivo electrical conductivity measurements during and after tumor electroporation: conductivity changes reflect the treatment outcome,Phys. Med. Biol., Sep. 17, 2009, 54, pp. 5949-5963. |
Ivorra, et al., Impedance analyzer for in vivo electroporation studies, Proceedings of the 28th IEEE EMBS Annual International Conference, IEEE, Aug. 30, 2006, pp. 5056-5059. |
Ivorra,“Bioimpedance monitoring for physicians: an overview.” Biomedical Applications Group, 35 pages (2002). |
Jan Ko et al, “New anti-huntingtin monoclonal antibodies: implications for huntingtin conformation and its binding proteins”, Brain Research Bulletin, Elsevier Science Ltd, Oxford, GB, (Oct. 1, 2001), vol. 56, No. 3-4, doi:10.1016/S0361-9230(01)00599-8, ISSN 0361-9230, pp. 319-329, XP002509144. |
Jarm et al., “Antivascular effects of electrochemotherapy: implications in treatment of bleeding metastases.” Expert Rev Anticancer Ther. vol. 10, pp. 729-746 (2010). |
Jensen et al., “Tumor volume in subcutaneous mouse xenografts measured by microCT is more accurate and reproducible than determined by 18FFDG-microPET or external caliper.” BMC medical Imaging vol. 8:16, 9 Pages 2008). |
Jiang, et al, Membrane-targeting approaches for enhanced cancer cell destruction with irreversible electroporation, Annuals of Biomedical Engineering, Aug. 15, 2013. |
Jordan, D.W., et al., “Effect of pulsed, high-power radiofrequency radiation on electroporation of mammalian cells”, Ieee Transactions on Plasma Science, 32(4): p. 1573-1578 (2004). |
Jossinet et al., Electrical Impedance Endo-Tomography: Imaging Tissue From Inside, IEEE Transactions on Medical Imaging, vol. 21, No. 6, Jun. 2002, pp. 560-565. |
Kanduser, et al, Cell membrane fluidity related to electroporation and resealing, Eur Biophys J, Oct. 8, 2006, 35, pp. 196-204. |
Katsuki, S., et al., “Biological effects of narrow band pulsed electric fields”, Ieee Transactions on Dielectrics and Electrical Insulation,. 14(3): p. 663-668 (2007). |
Kingham et al., “Ablation of perivascular hepatic malignant tumors with irreversible electroporation.” Journal of the American College of Surgeons, 2012. 215(3), p. 379-387. |
Kinosita et al., “Electroporation of cell membrane visualized under a pulsed-laser fluorescence microscope.” Biophysical Journal, vol. 53, pp. 1015-1019 (1988). |
Kinosita et al., “Voltage-induced pore formation and hemolysis of human erythrocytes.” Biochimica et Biophysica Acta (BBA)—Biomembranes, 471 (1977) pp. 227-242. |
Alberts et al., “Molecular Biology of the Cell,” 3rd edition, Garland Science, New York, 1994, 1 page. |
Bagla, Papadouris, Percutaneous irreversible electroporation of surgically unresectable pancreatic cancer: A case report, J Vasc Interv Radiol, 2012, 23, pp. 142-145. |
Blad, et al., Impedance Spectra of Tumour Tissue in Comparison with Normal Tissue; a Possible Clinical Application for Electrical Impedance Tomography, Physiol. Meas. 17 (1996) A105-A115. |
Boone, K., Barber, D. & Brown, B. Review—Imaging with electricity: report of the European Concerted Action on Impedance Tomography. J. Med. Eng. Technol. 21, 201-232 (1997). |
BPH Management Strategies: Improving Patient Satisfaction, Urology Times, May 2001, vol. 29, Supplement 1. 22 pages. |
Duraiswami, et al., Solution of Electrical Impedance Tomography Equations Using Boundary Element Methods, Boundary Element Technology XU, 1997, pp. 226-237. |
Edd et al., “Mathematical modeling of irreversible electroporation for treatment planning.” Technology in Cancer 20 Research and Treatment, vol. 6, No. 4, pp. 275-286 (2007). |
Edd, J., et al., In-Vivo Results of a New Focal Tissue Ablation Technique: Irreversible Electroporaton, IEEE Trans. 21 Biomed. Eng. 53 (2006) p. 1409-1415. |
Faroja, M., et al., “Irreversible Electroporation Ablation: Is the entire Damage Nonthermal?”, Radiology, 266(2), 28 462-470 (2013). |
Garcia, et al., “A Parametric Study Delineating Irreversible Electroporation from Thermal Damage Based on a 40 Minimally Invasive Intracranial Procedure,” Biomed Eng Online, vol. 10:34, 22 pages, 2011. |
Garcia, P. A., et al., “Towards a predictive model of electroporation-based therapies using pre-pulse electrical 41 measurements,” Conf Proc IEEE Eng Med Biol Soc, vol. 2012, pp. 2575-2578, 2012. |
Garcia, P. A., et al., “Non-thermal Irreversible Electroporation (N-TIRE) and Adjuvant Fractioned Radiotherapeutic Multimodal Therapy for Intracranial Malignant Glioma in a Canine Patient” Technol. Cancer Res. Treatment 10(1), 73-83 (2011). |
Glidewell, et al., The Use of Magnetic Resonance Imaging Data and the Inclusion of Anisotropic Regions in Electrical Impedance Tomography, Biomed, Sci. Instrum. 1993; 29: 251-7. |
Griffiths, Tissue Spectroscopy with Electrical Impedance Tomography: Computer Simulations, IEEE Transactions on Biomedical Engineering, vol. 42, No. 9, Sep. 1995. 8 pages. |
Gumerov, et al, The dipole approximation method and its coupling with the regular boundar yelement method for efficient electrical impedance tomography, BETECH Jun. 1999. |
Huang, Rubinsky, Micro-electroporation: improving the efficiency and understanding of electrical permeabilization of cells, Biomedical Microdevices, 1999, 2:2, pp. 145-150. |
Latouche, E. L., M. B. Sano, M. F. Lorenzo, R. V. Davalos, and R. C. G. Martin, “Irreversible electroporation for the ablation of pancreatic malignancies: A patient-specific methodology,” J. Surg. Oncol., vol. 115, No. 6, pp. 711-717, 2017. |
Lee, E.W., et al., “Imaging guided percutaneous irreversible electroporation: ultrasound and immunohistological correlation”, Technol Cancer Res Treat 6: 287-294 (2007). |
Li, W., et al., “The Effects of Irreversible Electroporation (IRE) on Nerves” PloS One, Apr. 2011, 6(4), e18831. 7 pages. |
Mercadal, Borja et al. “Dynamics of Cell Death After Conventional IRE and H-FIRE Treatments”, Annals of Biomedical Engineering, vol. 48, No. 5, 2020, p. 1451-1462. |
Naslund, Cost-Effectiveness of Minimally Invasive Treatments and Transurethral Resection (TURP) in Benign Prostatic Hyperplasia (BPH), (Abstract), Presented at 2001 AUA National Meeting,, Anaheim, CA, Jun. 5, 2001. 1 page. |
Neal II et al., “A Case Report on the Successful Treatment of a Large Soft-Tissue Sarcoma with Irreversible Electroporation,” Journal of Clinical Oncology, 29, pp. 1-6, 2011. |
Neal II, R. E., et al., “Successful Treatment of a Large Soft Tissue Sarcoma with Irreversible Electroporation”, Journal of Clinical Oncology, 29:13, e372-e377 (2011). |
Neal II, Robert E. and R.V. Davalos, The Feasibility of Irreversible Electroporation for the Treatment of Breast Cancer and Other Heterogeneous Systems, Ann Biomed Eng, 2009, 37(12): p. 2615-2625. |
PCT Application No. PCT/2011/062067, International Preliminary Report on Patentability dated May 28, 2013. 7 pages. |
PCT Application No. PCT/2011/066239, International Preliminary Report on Patentability dated Jun. 25, 2013. 7 pages. |
PCT Application No. PCT/US15/30429, International Report on Patentability dated Nov. 15, 2016. 7 pages. |
PCT Application No. PCT/US19/51731 (VTIP-A1001-PCT), International Preliminary Report on Patentability dated Mar. 23, 2021, 13 pages. |
Pending Application No. PCT/US21/51551 (VTIP-A1018-PCT), International Search Report and Written Opinion dated Dec. 29, 2021, 14 pages. |
Pending Application No. PCT/US23/15118 (VTIP-A1023-PCT), International Search Report and Written Opinion dated Jul. 31, 2023, 18 pages. |
Phillips, M., Maor, E. & Rubinsky, B. Nonthermal Irreversible Electroporation for Tissue Decellularization. J. Biomech. Eng, doi: :10.1115/1.4001882 (2010). 8 pages. |
Polak et al., “On the Electroporation Thresholds of Lipid Bilayers: Molecular Dynamics Simulation Investigations.” The Journal of Membrane Biology, vol. 246, pp. 843-850 (2013). |
Rebersek, M. and D. Miklav, “Advantages and Disadvantages of Different Concepts of Electroporation Pulse Generation,” Automatika 52(2011) 1, 12-19. |
Thomson et al., “Investigation of the safety of irreversible electroporation in humans,” J Vasc Interv Radiol, 22, pp. 611-621, 2011. |
TUNA—Suggested Local Anesthesia Guidelines, no date available. 1 page. |
Precision Office TUNA System, “When Patient Satisfaction is Your Goal.” Product Literature Published by VidaMed, Inc., 11 pages (2001). |
Number | Date | Country | |
---|---|---|---|
20210369325 A1 | Dec 2021 | US |
Number | Date | Country | |
---|---|---|---|
61392905 | Oct 2010 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 16222319 | Dec 2018 | US |
Child | 17346733 | US | |
Parent | 15612006 | Jun 2017 | US |
Child | 16222319 | US | |
Parent | 13273001 | Oct 2011 | US |
Child | 15612006 | US |